



chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5
chain bonds :
1-10 6-7 6-8 7-11
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom
Generic attributes :
11:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

Element Count :
Node 11: Limited
C,C4
S,S1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Ngrazier 10680346search

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 11:59:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  87815 TO ITERATE

  2.3% PROCESSED     2000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      1738707 TO  1773893
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:59:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 753988 TO ITERATE

 41.1% PROCESSED   720923 ITERATIONS                               310 ANSWERS

 51.4% PROCESSED   902313 ITERATIONS                               316 ANSWERS

 55.8% PROCESSED   978997 ITERATIONS                               316 ANSWERS

 57.0% PROCESSED  1000000 ITERATIONS                               316 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.52

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      1753988 TO  1753988
PROJECTED ANSWERS:             484 TO      624

L3           316 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10680346B.str
```




```
chain nodes :
6  7  8  10  16
ring nodes :
1  2  3  4  5  11  12  13  14  15  18  19  20  21  22  23
```

Ngrazier 10680346search

chain bonds :
1-10 6-7 6-8 7-11 7-16 12-18
ring bonds :
1-2 1-5 2-3 3-4 4-5 11-12 11-15 12-13 13-14 14-15 18-19 18-23 19-20 20-21
21-22 22-23
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-16 11-12 11-15 12-13 13-14 14-15
exact bonds :
12-18
normalized bonds :
18-19 18-23 19-20 20-21 21-22 22-23

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 12:03:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED 15 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

Ngrazier 10680346search

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           68 TO      532
PROJECTED ANSWERS:               0 TO        0

L5            0 SEA SSS SAM L4

=> s l4 full
FULL SEARCH INITIATED 12:03:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    469 TO ITERATE

100.0% PROCESSED      469 ITERATIONS                                  6 ANSWERS
SEARCH TIME: 00.00.01

L6            6 SEA SSS FUL L4

=>
Uploading C:\Program Files\Stnexp\Queries\10680346C.str
```






```
chain nodes :
6  7  8  10  16
ring nodes :
1  2  3  4  5  11  12  13  14  15
chain bonds :
1-10  6-7  6-8  7-11  7-16
ring bonds :
1-2  1-5  2-3  3-4  4-5  11-12  11-15  12-13  13-14  14-15
exact/norm bonds :
1-2  1-5  1-10  2-3  3-4  4-5  6-7  6-8  7-11  7-16  11-12  11-15  12-13  13-14  14-15


G1:H,CH3

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:CLASS  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:Atom  12:CLASS  13:Atom  14:Atom  15:Atom  16:CLASS



L7      STRUCTURE UPLOADED

=> s l7
SAMPLE SEARCH INITIATED 12:04:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    940 TO ITERATE

100.0% PROCESSED      940 ITERATIONS                                 11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
```

Ngrazier 10680346search

PROJECTED ITERATIONS: 16961 TO 20639
PROJECTED ANSWERS: 22 TO 418

L8 11 SEA SSS SAM L7

=> s l7 full
FULL SEARCH INITIATED 12:04:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17912 TO ITERATE

100.0% PROCESSED 17912 ITERATIONS 243 ANSWERS
SEARCH TIME: 00.00.01

L9 243 SEA SSS FUL L7

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 487.43 487.64

FILE 'CAPLUS' ENTERED AT 12:05:19 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Aug 2005 VOL 143 ISS 10
FILE LAST UPDATED: 29 Aug 2005 (20050829/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l9
L10 22 L9

=> d ed abs ibib hitstr l10

L10 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Apr 2005
GI



I



II

AB The invention relates to quinazoline derivs. I [R2 or the substituted pyrrolidinyloxy group is in the 6 or 7 position of the quinazoline ring; A is Ph or pyridyl; m is 0-3; n is 0-2; R1 is halo, cyano, nitro, hydroxy, carboxy, trifluoromethyl, alkyl, alkoxy, alkylsulfonyl, alkylureido, etc.; R2 is H, alkyl, cycloalkyl, cycloalkylalkyl or (un)substituted alkoxy; R3 is H, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, carbamoylalkyl, etc.; R4 is alkyl, alkoxy, cyano, halo, hydroxy or oxo; R5 is H or alkyl; R6 is H, alkyl, alkoxy, heterocyclyl, heteroaryl, etc.; or R5R6N is a ring], including processes for their preparation, pharmaceutical compns. containing them, and their use as antiproliferative agents in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. Thus, compound II was prepared by etherification of Boc-protected cis-4-hydroxy-D-proline Me ester with 4-chloro-7-methoxyquinazolin-6-ol and reaction of the product with 3-chloro-2-fluoroaniline in 4.0 M HCl/dioxane and acetonitrile, followed by reductive N-methylation, saponification, and amidation. Compound II showed IC50 = 0.008 nM for inhibition of EGFR tyrosine kinase protein phosphorylation and IC50 = 0.144 nM in the EGFR driven KB cell proliferation assay.

ACCESSION NUMBER: 2005:300434 CAPLUS
DOCUMENT NUMBER: 142:374111
TITLE: Preparation of proline quinazoline derivatives as antiproliferative agents
INVENTOR(S): Bradbury, Robert Hugh; Halsall, Christopher Thomas; Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Plowright, Alleyn

L10 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Ltd.
SOURCE: PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030757	A1	20050407	WO 2004-GB4085	20040922

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-22409 A 20030925
GB 2003-22534 A 20030926
OTHER SOURCE(S): MARPAT 142:374111
IT **849345-53-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline quinazoline derivs. as antiproliferative agents)
RN 849345-53-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-3-thienyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10680346search

=> d ed abs ibib hitstr 1-22

L10 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Apr 2005
GI



I



II

AB The invention relates to quinazoline derivs. I [R2 or the substituted pyrrolidinyloxy group is in the 6 or 7 position of the quinazoline ring; A is Ph or pyridyl; m is 0-3; n is 0-2; R1 is halo, cyano, nitro, hydroxy, carboxy, trifluoromethyl, alkyl, alkoxy, alkylsulfonyl, alkylureido, etc.; R2 is H, alkyl, cycloalkyl, cycloalkylalkyl or (un)substituted alkoxy; R3 is H, alkyl, cycloalkyl, alkylthio, alkylsulfinyl, carbamoylalkyl, etc.; R4 is alkyl, alkoxy, cyano, halo, hydroxy or oxo; R5 is H or alkyl; R6 is H, alkyl, alkoxy, heterocyclyl, heteroaryl, etc.; or R5R6N is a ring], including processes for their preparation, pharmaceutical compns. containing them, and their use as antiproliferative agents in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. Thus, compound II was prepared by etherification of Boc-protected cis-4-hydroxy-D-proline Me ester with 4-chloro-7-methoxyquinazolin-6-ol and reaction of the product with 3-chloro-2-fluoroaniline in 4.0 M HCl/dioxane and acetonitrile, followed by reductive N-methylation, saponification, and amidation. Compound II showed IC50 = 0.008 nM for inhibition of EGFR tyrosine kinase protein phosphorylation and IC50 = 0.144 nM in the EGFR driven KB cell proliferation assay.

ACCESSION NUMBER: 2005:300434 CAPLUS
DOCUMENT NUMBER: 142:374111
TITLE: Preparation of proline quinazoline derivatives as antiproliferative agents
INVENTOR(S): Bradbury, Robert Hugh; Halsall, Christopher Thomas; Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Plowright, Alleyn

L10 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Ltd.
SOURCE: PCT Int. Appl., 198 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030757	A1	20050407	WO 2004-GB4085	20040922

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-22409 A 20030925
GB 2003-22534 A 20030926
OTHER SOURCE(S): MARPAT 142:374111
IT 849345-53-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of proline quinazoline derivs. as antiproliferative agents)
RN 849345-53-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-N-3-thienyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 24 Sep 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Sulfonamide lactams of formula I [wherein X = (un)substituted (CH2)m; m = 1-3; R1 = (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl, cycloheteroalkyl; R2, R3 = independently H, (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl, cycloheteroalkyl; R4, R4a, R5, R5a = independently H, OH, alkoxy, CO2H and derivs., CONH2 and derivs., S(O)qH and derivs., SO2NH2 and derivs., etc. (un)substituted alk(en/yn)yl, cycloalkyl, hetero/aryl, cycloheteroalkyl; q = 0-2; R6, R6a = independently H, (un)substituted alk(en/yn)yl, cycloalkyl, substituted hetero/aryl, cycloheteroalkyl; R7, R8 = independently (un)substituted (CH2)n-H or R7NR8 = (un)substituted cycloheteroalkyl; n = 1-4; with the proviso that certain compds. are absent; their pharmaceutically acceptable salts, stereoisomers and prodrugs] were prepared as inhibitors of Factor Xa and useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses (no data). For instance, reacting amine II with naphthalene-2-sulfonyl chloride in CH2Cl2 in the presence of TEA for 30 min at room temperature gave sulfonamide III in 66% yield.

ACCESSION NUMBER: 2004:780362 CAPLUS
DOCUMENT NUMBER: 141:295864
TITLE: Preparation of sulfonamide lactams as Factor Xa inhibitors
INVENTOR(S): O'Connor, Stephen P.; Lawrence, Michael; Shi, Yan; Stein, Philip D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 257 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004186134	A1	20040923	US 2003-374299	20030226

PRIORITY APPLN. INFO.: US 2003-374299 20030226
OTHER SOURCE(S): MARPAT 141:295864
IT 445277-00-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of sulfonamide lactams as factor Xa inhibitors and anticoagulants)
RN 445277-00-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L10 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 May 2004
GI


I


II


III


IV

AB A fungicidally active compound I, II, or III [wherein Het = (un)substituted 5- or 6-membered heterocyclic ring containing one to three O, N, and/or S atoms, provided that the ring is not 1,2,3-triazole; R1 and R2 = independently H, halo, or Me; R3 = (un)substituted (cyclo)alkyl, alkenyl, alkynyl, Ph, heterocyclyl; R7 and R8 = independently H, halo, or (halo)alkyl] were prepared for use as active ingredients in agricultural or horticultural compns. for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi. For example, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid was amidated with [2-(bicyclopropyl-2-yl)thiophen-3-yl]amine in the presence of TEA and N,N-bis(2-oxooxazolidinyl)phosphinic acid chloride in CH2Cl2 to give trans-IV (97% purity). The latter showed excellent activity against Puccinia recondita on wheat (0-5% infestation) and showed good activity against Podosphaera leucotricha on apple, Venturia inaequalis on apple, Erysiphe graminis on barley, Pyrenophora teres on barley, Alternaria solani on tomato, and Uncinula necator on grape (<20% infestation for each).

ACCESSION NUMBER: 2004:390242 CAPLUS
DOCUMENT NUMBER: 140:406731
TITLE: Preparation of N-(cyclopropylthienyl)carboxamides as fungicides
INVENTOR(S): Ehrenfreund, Josef; Tobler, Hans; Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations Ag, Switz.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039799	A1	20040513	WO 2003-EP11805	20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501739	AA	20040513	CA 2003-2501739	20031024
EP 1556377	A1	20050727	EP 2003-776869	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: GB 2002-25554 A 20021101
WO 2003-EP11805 W 20031024

OTHER SOURCE(S): MARPAT 140:406731
IT 688322-46-5P 688322-47-6P 688322-48-7P
688322-49-8P 688322-50-1P 688322-51-2P
688322-52-3P 688322-53-4P 688322-54-5P
688322-55-6P 688322-56-7P 688322-57-8P
688322-58-9P 688322-59-0P 688322-60-3P
688322-61-4P 688322-62-5P 688322-63-6P
688322-64-7P 688322-65-8P 688322-66-9P
688322-67-0P 688322-68-1P 688322-69-2P
688322-70-5P 688322-71-6P 688322-72-7P
688322-73-8P 688322-74-9P 688322-75-0P
688322-76-1P 688322-77-2P 688322-78-3P
688322-79-4P 688322-80-7P 688322-81-8P
688322-82-9P 688322-83-0P 688322-84-1P
688322-85-2P 688322-86-3P 688322-87-4P
688322-88-5P 688322-89-6P 688322-90-9P
688322-91-0P 688322-92-1P 688322-93-2P
688322-94-3P 688322-95-4P 688322-96-5P
688322-97-6P 688322-98-7P 688322-99-8P
688323-00-4P 688323-01-5P 688323-02-6P
688323-03-7P 688323-04-8P 688323-05-9P
688323-06-0P 688323-07-1P 688323-08-2P
688323-09-3P 688323-10-6P 688323-11-7P
688323-12-8P 688323-13-9P 688323-14-0P
688323-15-1P 688323-16-2P 688323-17-3P
688323-18-4P 688323-19-5P 688323-20-8P
688323-21-9P 688323-22-0P 688323-23-1P
688325-61-3P 688325-62-4P 688325-63-5P
688325-64-6P 688325-66-8P 688325-67-9P
688325-68-0P 688325-69-1P 688325-70-4P
688325-71-5P 688325-72-6P 688325-73-7P
688325-74-8P 688325-75-9P 688325-76-0P
688325-77-1P 688325-78-2P 688325-79-3P
688325-80-6P 688325-81-7P 688325-82-8P

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
688325-83-9P 688325-84-0P 688325-85-1P
688325-86-2P 688325-87-3P 688325-88-4P
688325-89-5P 688325-90-8P 688325-91-9P
688325-92-0P 688325-93-1P 688325-94-2P
688325-95-3P 688325-96-4P 688325-97-5P
688325-98-6P 688325-99-7P 688326-00-3P
688326-01-4P 688326-02-5P 688326-03-6P
688326-04-7P 688326-05-8P 688326-06-9P
688326-07-0P 688326-08-1P 688326-09-2P
688326-10-5P 688326-11-6P 688326-12-7P
688326-13-8P 688326-15-0P 688326-16-1P
688326-17-2P 688326-18-3P 688326-19-4P
688326-20-7P 688326-21-8P 688326-22-9P
688326-23-0P 688326-24-1P 688326-25-2P
688326-26-3P 688326-27-4P 688326-28-5P
688326-29-6P 688326-30-9P 688326-31-0P
688326-32-1P 688326-33-2P 688326-34-3P
688326-35-4P 688326-36-5P 688326-37-6P
688326-38-7P 688326-39-8P 688326-40-1P
688328-21-4P 688328-22-5P 688328-23-6P
688328-24-7P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fungicide; prepn. of N-(cyclopropylthienyl)carboxamides as fungicides)

RN 688322-46-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-ethylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-47-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-ethylcyclopropyl)-3-thienyl]-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-48-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(2-propylcyclopropyl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-49-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-(2-propylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-50-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-51-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-52-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-53-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-54-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1-ethyl-4-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-55-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-59-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-60-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688322-61-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)-3-thienyl]-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688322-62-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(2-methylpropyl)cyclopropyl]-3-

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-56-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-ethyl-2-fluoro-4-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-57-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-2-fluoro-1-methyl-N-[2-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-58-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-butylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-63-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-64-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[2-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-65-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(methoxymethyl)-N-[2-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688322-66-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-67-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-68-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-69-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[2-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-70-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688322-71-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688322-72-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-73-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(2-pentylcyclopropyl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-74-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(3-methylbutyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-75-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-[2-(3-methylbutyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688322-76-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-hexylcyclopropyl)-3-thienyl]-1-methyl-4-

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-77-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-78-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-79-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688322-80-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-81-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclobutylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-82-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclobutylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-83-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-84-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-85-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688322-86-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-(2-cyclopentylcyclopropyl)-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-87-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclopentylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688322-88-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-(2-cyclopentylcyclopropyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-89-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-90-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-91-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-92-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-(2-cyclohexylcyclopropyl)-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-93-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3-cyclohexyl-2,2-difluorocyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-94-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclohexylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-95-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-(2-cyclohexylcyclopropyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688322-96-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688322-97-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)-3-thienyl]-1-ethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688322-98-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688322-99-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688323-00-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[2-(2-cycloheptylcyclopropyl)-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688323-01-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cycloheptylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688323-02-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[2-(2-cycloheptylcyclopropyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688323-03-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclooctylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688323-04-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(2-cyclooctylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688323-05-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(2-phenylcyclopropyl)-3-thienyl]-4-

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688323-06-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688323-07-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[2-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688323-08-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688323-09-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688323-10-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-fluorophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688323-11-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[2-[2-(4-fluorophenyl)cyclopropyl]-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688323-12-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-chlorophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688323-13-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-chlorophenyl)cyclopropyl]-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688323-14-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-bromophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688323-15-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(4-bromophenyl)cyclopropyl]-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688323-16-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(2-thienyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688323-17-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[2-(3-thienyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688323-18-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(2-furanyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688323-19-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[2-(3-furanyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688325-61-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-ethylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-62-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-ethylcyclopropyl)-3-thienyl]-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-63-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-(2-propylcyclopropyl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-64-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[4-(2-propylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688323-20-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688323-21-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688323-22-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688323-23-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[2-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688325-66-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-67-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-68-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-69-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688325-70-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1-ethyl-4-methyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-71-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-72-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-ethyl-2-fluoro-4-methyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688325-73-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-2-fluoro-1-methyl-N-[4-[2-(1-methylethyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-74-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-butylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-75-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-butylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688325-76-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-butylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688325-77-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-butylcyclopropyl)-3-thienyl]-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688325-78-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-79-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[4-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688325-80-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[4-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-81-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(methoxymethyl)-N-[4-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-82-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[4-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-83-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[4-[2-(2-methylpropyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688325-84-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-85-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[4-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688325-86-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688325-87-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[4-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688325-88-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[4-[2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688325-89-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-(2-pentylcyclopropyl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-90-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-[2-(3-methylbutyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-91-9 CAPLUS

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[4-[2-(3-methylbutyl)cyclopropyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688325-92-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-hexylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-93-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-94-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688325-95-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688325-96-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(4-[1,1'-bicyclopropyl]-2-yl-3-thienyl)-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688325-97-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclobutylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688325-98-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclobutylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688325-99-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclopentylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688326-00-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclopentylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-01-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclopentylcyclopropyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688326-05-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclohexylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-06-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclohexylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-07-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclohexylcyclopropyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688326-02-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[4-(2-cyclopentylcyclopropyl)-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-03-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclopentylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688326-04-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[4-(2-cyclopentylcyclopropyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688326-08-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[4-(2-cyclohexylcyclopropyl)-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-09-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(3-cyclohexyl-2,2-difluorocyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-10-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclohexylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688326-11-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[4-(2-cyclohexylcyclopropyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688326-12-7 CAPLUS

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cycloheptylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-13-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cycloheptylcyclopropyl)-3-thienyl]-1-ethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-15-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cycloheptylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-16-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cycloheptylcyclopropyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688326-17-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[4-(2-cycloheptylcyclopropyl)-3-thienyl]-2-fluoro-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-18-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cycloheptylcyclopropyl)-3-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688326-19-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[4-(2-cycloheptylcyclopropyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688326-20-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclooctylcyclopropyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688326-21-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-(2-cyclooctylcyclopropyl)-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-22-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-(2-phenylcyclopropyl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-23-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[4-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688326-24-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[4-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688326-25-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[4-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688326-26-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[4-(2-phenylcyclopropyl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688326-27-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(4-fluorophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-28-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[4-[2-(4-fluorophenyl)cyclopropyl]-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688326-29-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(4-chlorophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-30-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(4-chlorophenyl)cyclopropyl]-3-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-31-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(4-bromophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-32-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(4-bromophenyl)cyclopropyl]-3-thienyl]-4-

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688326-36-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(3-furanyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-37-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-38-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[4-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688326-33-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-[2-(2-thienyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-34-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[4-[2-(3-thienyl)cyclopropyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688326-35-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[2-(2-furanyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688326-39-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[4-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688326-40-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[4-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-3-thienyl]- (9CI) (CA INDEX NAME)



RN 688328-21-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(1R,2R)-2-(1,1-dimethylethyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688328-22-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S)-[1,1'-bicyclopropyl]-2-yl-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 688328-23-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(1R,2R)-2-(4-fluorophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688328-24-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-[(1R,2R)-2-(4-chlorophenyl)cyclopropyl]-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 14 Apr 2004
AB DNA binding ligands with potent antimicrobial activity against Gram-pos. bacteria were further optimized by variation of the internal aromatic amino acids. This modification led to compds. with improved in vivo efficacy in lethal murine models of peritonitis (methicillin-resistant S. aureus, MRSA) and lung infection (S. pneumoniae).
ACCESSION NUMBER: 2004:303262 CAPLUS
DOCUMENT NUMBER: 141:64377
TITLE: DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids
AUTHOR(S): Burli, Roland W.; Kaizerman, Jacob A.; Duan, Jian-Xin; Jones, Peter; Johnson, Kirk W.; Iwamoto, Mari; Truong, Kiet; Hu, Wenhao; Stanton, Timothy; Chen, Alfred; Touami, Sofia; Gross, Matthew; Jiang, Vernon; Ge, Yigong; Moser, Heinz E.
CORPORATE SOURCE: Genesoft Pharmaceuticals, South San Francisco, CA, 94080, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2067-2072
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 710950-17-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DNA binding ligands with in vivo efficacy in murine models of bacterial infection and structure-activity relationship)
RN 710950-17-7 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[1-methyl-5-[[[5-[[[1-methyl-5-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]amino]carbonyl]-3-thienyl]amino]carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Dec 2003
GI



AB The invention relates to synthetic excitatory amino acid prodrugs for the treatment of neurol. disorders and psychiatric disorders. Bicyclic amino acids I [A is H-Q1-10, where Q is aminoacyl; X is O, S, SO, SO2, or substituted methylene; R1 is H or F; R2 is H, F, or OH] or their pharmaceutically-acceptable salts are claimed. Thus, prodrug II.HCl was prepared via peptide coupling reaction and shown to exhibit comparable concentration in rat plasma to that of the non-prodrug form.
ACCESSION NUMBER: 2003:991499 CAPLUS
DOCUMENT NUMBER: 140:42463
TITLE: Preparation of prodrugs of excitatory amino acids
INVENTOR(S): Moher, Eric David; Monn, James Allen; Pedregal-Tercero, Concepcion
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Collado, Cano Ivan; Blanco-Urgoiti, Jamie Gonzalo
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104217	A2	20031218	WO 2003-US15405	20030606
WO 2003104217	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488167	AA	20031218	CA 2003-2488167	20030606
EP 1517915	A2	20050330	EP 2003-757266	20030606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			EP 2002-380120	A 20020611
			EP 2002-380121	A 20020611
			US 2002-415936P	P 20021003

L10 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
US 2002-415937P P 20021003
WO 2003-US15405 W 20030606

OTHER SOURCE(S): MARPAT 140:42463
IT 635317-69-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of prodrugs of excitatory amino acids)
RN 635317-69-0 CAPLUS
CN 2-Thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid, 4-[[[(2S)-1-[(1,1-dimethylethoxy)carbonyl]-2-pyrrolidinyl]carbonyl]amino]-, dimethyl ester, 2,2-dioxide, (1R,4S,5S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Mar 2003
GI



I

AB 132 CBI analogs I [X, Y = arylene, heteroarylene] of CC 1065 and the duocarmycins having dimeric monocyclic, bicyclic, and tricyclic heteroaroms. substituents were synthesized by a parallel route. The resultant analogs were evaluated with respect to their catalytic and cytotoxic activities. The relative contribution of the various dimeric monocyclic, bicyclic, and tricyclic heteroaroms. substituents within the DNA binding domain were characterized. Several of the resultant CBI analogs of CC 1065 and the duocarmycins were characterized as having enhanced catalytic and cytotoxic activities and were identified as having utility as anti-cancer agents. Thus, I (X = Y = -4-C6H4-) was prepared starting from 4-H2NC6H4CO2H and the hydrochloride salt of seco-CBI.
ACCESSION NUMBER: 2003:221652 CAPLUS
DOCUMENT NUMBER: 138:255007
TITLE: Preparation of CBI analogues of CC 1065 and the duocarmycins for therapeutic use as anticancer agents
INVENTOR(S): Boger, Dale L.
PATENT ASSIGNEE(S): The Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022806	A2	20030320	WO 2002-US28749	20020909
WO 2003022806	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459308	AA	20030320	CA 2002-2459308	20020909
EP 1423110	A2	20040602	EP 2002-798201	20020909
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

L10 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
JP 2005502703 T2 20050127 JP 2003-526882 20020909
US 2005014700 A1 20050120 US 2004-489006 20040827
PRIORITY APPLN. INFO.: US 2001-318179P P 20010907
WO 2002-US28749 W 20020909

OTHER SOURCE(S): MARPAT 138:255007
IT 372953-56-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and evaluation of tetrahydrocyclopropa[c]benz[e]indol-4-one analogs of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain)
RN 372953-56-5 CAPLUS
CN Carbamic acid, [5-[[[5-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-3-thienyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 502171-77-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and evaluation of tetrahydrocyclopropa[c]benz[e]indol-4-one analogs of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain)
RN 502171-77-9 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Jan 2003
GI



I



II

AB Title compds. I [wherein R1 and R6 = independently H, halo, CF3, alkyl, alkylthio, alkoxy, CN, NO2, NH2, Ph, OPh, SPh, CH2Ph, OCH2Ph, SCH2Ph, or (un)substituted amido, carbamido, sulfonyl, etc.; R2 = H, halo, CF3, OH, alkyl, alkoxy, CHO, CN, NO2, (un)substituted amino, or alkylsulfonyl; R3 = CO2H, OPO3H2, SO3H, etc.; R4 = H, CF3, alkyl, alkoxy, (alkyl)cycloalkyl, CHO, halo, etc.; R5 = alkyl, alkoxy, (alkyl)cycloalkyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as phospholipase enzyme inhibitors. For example, 5-nitroindole was C3-alkylated (55%) with Me 4-(bromomethyl)-3-methoxybenzoate in dioxane, N-alkylated (57%) with 1-iodopropane in a solution of THF and NaH, and converted to the amine (80%) by hydrogenation using Pt/C. The amine was converted to the carbamate (39%) by addition of cyclopentyl chloroformate in CH2Cl2 and 4-methylmorpholine, and the resultant ester was hydrolyzed to yield II (71%). The latter inhibited cytosolic phospholipase A2 (cPLA2) by 50% at a concentration of 170 μM in a coumarin assay and reduced footpad volume by 16.61% at a dose of 5 mg/Kg IV in a carrageenan-induced footpad edema test on rats. Thus, I are useful for treatment of inflammatory conditions, such as arthritis, inflammatory bowel disease, and asthma (no data).
ACCESSION NUMBER: 2003:1275 CAPLUS
DOCUMENT NUMBER: 138:55866
TITLE: Preparation of indole derivatives as phospholipase enzyme inhibitors for treatment of inflammatory conditions
INVENTOR(S): Seehra, Jasbir S.; McKew, John C.; Lovering, Frank; Bemis, Jean E.; Xiang, Yibin; Chen, Lihren; Knopf, John L.
PATENT ASSIGNEE(S): Genetics Institute, LLC, USA
SOURCE: U.S., 57 pp., Cont.-in-part of U. S. Ser. No. 256,062, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

L10 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6500853	B1	20021231	US 2000-686616	20001011
PRIORITY APPLN. INFO.:			US 1998-113674P	P 19980228
			US 1999-256062	B2 19990224

OTHER SOURCE(S): MARPAT 138:55866
IT **241497-74-5DP**, 3-Thiophenecarboxylic acid, 4-[[[5-[(cyclopentylcarbonyl)amino]-1-(diphenylmethyl)-1H-indol-3-yl]carbonyl]amino]-, ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indole derivs. as phospholipase enzyme inhibitors for treatment of inflammatory conditions)
RN 241497-74-5 CAPLUS
CN 3-Thiophenecarboxylic acid, 4-[[[5-[(cyclopentylcarbonyl)amino]-1-(diphenylmethyl)-1H-indol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **241497-74-5P**, 3-Thiophenecarboxylic acid, 4-[[[5-[(cyclopentylcarbonyl)amino]-1-(diphenylmethyl)-1H-indol-3-yl]carbonyl]amino]-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phospholipase inhibitor; preparation of indole derivs. as phospholipase enzyme inhibitors for treatment of inflammatory conditions)
RN 241497-74-5 CAPLUS
CN 3-Thiophenecarboxylic acid, 4-[[[5-[(cyclopentylcarbonyl)amino]-1-(diphenylmethyl)-1H-indol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Dec 2002
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, F, Cl, CN, CF3, OH, N(R2)2, OR2, etc.; R2-3 = H, alkyl, heteroalkyl; n = 1-25; Y = alkylene, (hetero)aromatic; Z = O, N; m = 1 if Z = O, m = 2 if Z = N] were prepared For instance, II (preparation given) was coupled to 4-chloro-2-fluorobenzoic acid, the product saponified and the resulting carboxylic acid coupled to N-(2-aminoethyl)morpholine to give III. III had MIC ≤ 4 μg/mL against B. cereus, E. faecalis, E. faecium, S. aureus, S. epidermidis and S. pneumoniae. A number of compds. of the invention were screened for their ability to bind to three DNA sites (binding data tabulated).
ACCESSION NUMBER: 2002:964476 CAPLUS
DOCUMENT NUMBER: 138:39101
TITLE: Preparation of antipathogenic poly-pyrrole-benzamide compounds
INVENTOR(S): Burli, Roland W.; Kaizerman, Jacob A.; Jones, Peter
PATENT ASSIGNEE(S): Genesoft, Inc., USA
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002101007	A2	20021219	WO 2002-US17951	20020606
WO 2002101007	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003236198	A1	20031225	US 2002-165764	20020606
PRIORITY APPLN. INFO.:			US 2001-298206P	P 20010613
			US 2001-342309P	P 20011221

OTHER SOURCE(S): MARPAT 138:39101
IT **478803-58-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of poly-pyrrole-benzamide and related analogs as antibiotics and DNA binders)
RN 478803-58-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[[4-[(4-chloro-2-fluorobenzoyl)amino]-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-N-[5-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]-3-thienyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L10 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L10 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Aug 2002
GI



I

AB Title compds. [I; X = (substituted) (CH2)m; m = 1-3; R1 = (substituted) alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.; R2, R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R4, R41, R5, R51 = H, OH, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, alkoxy, etc.; R6, R61 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R7, R8 = (substituted) (CH2)nH; n = 1-4; R7R8N = (substituted) cycloheteroalkyl], were prepared as cardiovascular agents (no data). 974 I, including (II), were prepared

ACCESSION NUMBER: 2002:594840 CAPLUS
DOCUMENT NUMBER: 137:154858
TITLE: Preparation of arylsulfonamidopiperidones as inhibitors of Factor Xa.
INVENTOR(S): Stein, Philip P.; O'Connor, Stephen P.; Lawrence, R. Michael; Shi, Yan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060894	A2	20020808	WO 2002-US2542	20020128
WO 2002060894	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2436774	AA	20020808	CA 2002-2436774	20020128
EP 1358178	A2	20031105	EP 2002-717381	20020128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518688	T2	20040624	JP 2002-561043	20020128
US 6555542	B1	20030429	US 2002-59621	20020129
PRIORITY APPLN. INFO.:			US 2001-264964P P	20010130

L10 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
WO 2002-US2542 W 20020128

OTHER SOURCE(S): MARPAT 137:154858
IT 445277-00-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonamidopiperidones as inhibitors of Factor Xa)
RN 445277-00-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-piperidinyl]acetyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 18 May 2002
GI



I II

AB The title compds. [I; X = O, S; R1 = CF3, CF2H, CFH2; R2 = alkyl, haloalkyl, alkoxyalkyl, haloalkoxyalkyl; R3 = H, Me, CF3, F; Q = substituted Ph, 2-thienyl, 3-thienyl] which have plant-protecting properties and are suitable for protecting plants against infestation by phytopathogenic microorganisms, were prepared Thus, treating 1-methyl-4-trifluoromethylpyrrole-3-carboxylic acid with oxalyl chloride in the presence of a catalytic amount of DMF in CH2Cl2 followed by addition of the resulting acid chloride to a solution of 2-(1,3-dimethylbutyl)phenylamine and Et3N in CH2Cl2 afforded II. Compds. I showed good activity (< 20% infestation) against Puccinia recondita (brown rust) on wheat.

ACCESSION NUMBER: 2002:368451 CAPLUS
DOCUMENT NUMBER: 136:369602
TITLE: Preparation of pyrrolecarboxamides and pyrrolecarbothioamides as agrochemical fungicides
INVENTOR(S): Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038542	A1	20020516	WO 2001-EP12830	20011106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2426033	AA	20020516	CA 2001-2426033	20011106
AU 2002023668	A5	20020521	AU 2002-23668	20011106
EP 1341757	A1	20030910	EP 2001-993599	20011106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015200	A	20040217	BR 2001-15200	20011106
EG 23122	A	20040428	EG 2001-1173	20011106
JP 2004513163	T2	20040430	JP 2002-541078	20011106
US 2005119130	A1	20050602	US 2003-416219	20011106

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

ZA 2003003012	A	20040520	ZA 2003-3012	20030416
PRIORITY APPLN. INFO.:			GB 2000-27284	A 20001108
			GB 2000-30268	A 20001212
			WO 2001-EP12830	W 20011106

OTHER SOURCE(S): MARPAT 136:369602
IT 424832-40-6P 424832-41-7P 424832-42-8P
424832-43-9P 424832-44-0P 424832-45-1P
424832-46-2P 424832-47-3P 424832-48-4P
424832-49-5P 424832-50-8P 424832-51-9P
424832-52-0P 424832-53-1P 424832-54-2P
424832-55-3P 424832-56-4P 424832-57-5P
424832-58-6P 424832-59-7P 424832-60-0P
424832-61-1P 424832-62-2P 424832-63-3P
424832-64-4P 424832-65-5P 424832-66-6P
424832-67-7P 424832-68-8P 424832-69-9P
424832-70-2P 424832-71-3P 424832-72-4P
424832-73-5P 424832-74-6P 424832-75-7P
424832-76-8P 424832-77-9P 424832-78-0P
424832-79-1P 424832-80-4P 424832-81-5P
424832-82-6P 424832-83-7P 424832-84-8P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolecarboxamides and pyrrolecarbothioamides as agrochem. fungicides)
RN 424832-40-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-41-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-42-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-[3-methyl-1-(trifluoromethyl)butyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-43-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[2-[4,4,4-trifluoro-1-methyl-3-(trifluoromethyl)butyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 424832-44-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylpentyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-45-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylpentyl)-3-thienyl]-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-49-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylbutyl)-3-thienyl]-2-fluoro-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-50-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylbutyl)-3-thienyl]-2-fluoro-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-51-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylpentyl)-3-thienyl]-2-fluoro-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-52-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1-methyl-N-[2-(3-methyl-1-

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-46-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylbutyl)-5-fluoro-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-47-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylbutyl)-4-fluoro-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-48-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3-ethyl-1-methylpentyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

(trifluoromethyl)butyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-53-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1-methyl-N-[2-[3-methyl-1-(trifluoromethyl)pentyl]-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-54-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 424832-55-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[2-(1,3-dimethylpentyl)-3-thienyl]-1-methyl- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-56-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[2-[3-methyl-1-(trifluoromethyl)butyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 424832-57-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylbutyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 424832-58-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,3-dimethylpentyl)-3-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-59-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[2-[3-methyl-1-(trifluoromethyl)butyl]-3-thienyl]- (9CI) (CA INDEX NAME)



RN 424832-60-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.1]hepta-2,5-dien-2-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-61-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.1]hept-2-en-2-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-62-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.1]hept-5-en-2-yl-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-63-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 424832-64-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-4-fluoro-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-65-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-4-(trifluoromethyl)-N-[2-[(1R,2S,4S)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]-3-thienyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-66-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-3-thienyl]-1-(methoxymethyl)-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-67-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-3-thienyl]-4-(difluoromethyl)-1-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-68-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]octa-2,5-dien-2-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-69-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-en-2-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-70-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.2]oct-5-en-2-yl-3-thienyl]-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 424832-71-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-72-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-3-thienyl)-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-73-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-4-fluoro-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 424832-74-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-4-fluoro-3-thienyl)-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-75-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-3-thienyl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 424832-76-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.1]hept-5-en-2-yl-3-thienyl]-2-fluoro-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-77-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-3-thienyl]-2-fluoro-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-78-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.1]hept-5-en-2-yl-3-thienyl]-2-fluoro-1-(methoxymethyl)-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-81-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-3-thienyl)-2-fluoro-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-82-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-3-thienyl)-2-fluoro-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 424832-83-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-3-thienyl]-1,2-dimethyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 424832-79-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-3-thienyl]-2-fluoro-1-(methoxymethyl)-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 424832-80-4 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1R,2S,4R)-bicyclo[2.2.2]oct-5-en-2-yl-3-thienyl]-2-fluoro-1-methyl-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Relative stereochemistry.



RN 424832-84-8 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-bicyclo[2.2.2]oct-2-yl-3-thienyl)-1,2-dimethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Dec 2001
GI



I



II

AB The development of a solution-phase synthesis of distamycin A and its extension to the preparation of 2640 analogs are described. Thus, solution-phase synthesis techniques with reaction workup and purification employing acid/base liquid-liquid extns. were used in the multistep preparation of distamycin A (8 steps, 40 overall yield) and a prototypical library of 2640 analogs providing intermediates and final products that are ≥ 95 pure on conventional reaction scales. Screening the prototypical library provided compds. that are 1000 times more potent than distamycin A in cytotoxic assays (I, Boc = tert-butoxycarbonyl, IC50 = 29 nM, L1210), that bind to poly[dA]-poly[dT] with comparable affinity, and that exhibit an altered DNA binding sequence selectivity. Several candidates were identified which bound the five base-pair AT-rich site of the PSA-ARE-3 sequence, and one (II, R = 4-dimethylaminobutyryl; K = 3.2 x 106 M-1) maintained the high affinity binding (K = 4.5 x 106 M-1) to the ARE-consensus sequence containing a GC base-pair interrupted five base-pair AT-rich site suitable for inhibition of gene transcription initiated by hormone insensitive androgen receptor dimerization and DNA binding characteristic of therapeutic resistant prostate cancer.

ACCESSION NUMBER: 2001:923774 CAPLUS
DOCUMENT NUMBER: 136:54024
TITLE: Preparation of distamycin A analogs and screening for DNA binding and cytotoxic activities

L10 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INVENTOR(S): Boger, Dale L.
PATENT ASSIGNEE(S): Scripps Research Institute, USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096313	A1	20011220	WO 2001-US19404	20010614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-211760P P 20000614
OTHER SOURCE(S): MARPAT 136:54024
IT 292069-27-3P 292069-37-5P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of distamycin A analogs and screening for DNA binding and cytotoxic activities)
RN 292069-27-3 CAPLUS
CN Benzo[1,2-b:4,3-b']dipyrrole-2-carboxylic acid, 6-[[4-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-2-thienyl]carbonyl]-3,6,7,8-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)



RN 292069-37-5 CAPLUS
CN Benzo[1,2-b:4,3-b']dipyrrole-2-carboxylic acid, 6-[[4-[[[4-[[4-(dimethylamino)-1-oxobutyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-2-thienyl]carbonyl]-3,6,7,8-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 Oct 2001
AB Charged compds. are provided that have one or more regions of localized pos. charge, as are compns. comprising such compds., methods of synthesizing such compds., methods of screening such compds. to identify those having anti-infective activity, and methods of using such compds. to prevent or inhibit infections. These compds., and compns. containing them, have multiple applications, including use in human and animal medicine and in agriculture.
ACCESSION NUMBER: 2001:747848 CAPLUS
DOCUMENT NUMBER: 135:298753
TITLE: Charged compounds having a nucleic acid-binding moiety, their preparation, and their use as antiinfective agents
INVENTOR(S): Ge, Yigong; Taylor, Matthew J.; Baird, Eldon E.; Moser, Heinz E.; Burli, Roland W.
PATENT ASSIGNEE(S): Genesoft, Inc., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074898	A2	20011011	WO 2001-US8252	20010314
WO 2001074898	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2403537	AA	20011011	CA 2001-2403537	20010314
US 2002065227	A1	20020530	US 2001-808729	20010314
US 6555693	B2	20030429		
JP 2003529609	T2	20031007	JP 2001-572587	20010314
EP 1265921	A1	20021218	EP 2001-954573	20010316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003211508	A1	20031113	US 2002-278870	20021022

PRIORITY APPLN. INFO.: US 2000-189930P P 20000316
US 2001-808729 A3 20010314
WO 2001-US8252 W 20010314
OTHER SOURCE(S): MARPAT 135:298753
IT 365211-00-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(charged compds. with nucleic acid-binding moiety, preparation, and use as antiinfective agents)
RN 365211-00-3 CAPLUS
CN 3-Isothiazolecarboxamide, 4-chloro-5-[[3-(dimethylamino)propyl]amino]-N-[5-[[[5-[[[5-[[3-(dimethylamino)propyl]amino]carbonyl]-3-thienyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

L10 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



L10 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 Sep 2001
AB The solution-phase, parallel synthesis and evaluation of a library of 132 (+)-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogs of CC-1065 and the duocarmycins containing dimeric monocyclic, bicyclic, and tricyclic heteroarom. replacements for the DNA-binding domain are described. This systematic study revealed clear trends in the structural requirements for observation of potent cytotoxic activity and DNA alkylation efficiency, the range of which spans a magnitude of ≥10 000-fold. Combined with related studies, these results highlight that the role of the DNA-binding domain goes beyond simply providing DNA-binding selectivity and affinity (10-100-fold enhancement in properties), consistent with the proposal that it contributes significantly to catalysis of the DNA alkylation reaction accounting for as much as an addnl. 1000-fold enhancement in properties.
ACCESSION NUMBER: 2001:667407 CAPLUS
DOCUMENT NUMBER: 135:357786
TITLE: Parallel Synthesis and Evaluation of 132 (+)-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) Analogues of CC-1065 and the Duocarmycins Defining the Contribution of the DNA-Binding Domain
AUTHOR(S): Boger, Dale L.; Schmitt, Harald W.; Fink, Brian E.; Hedrick, Michael P.
CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Journal of Organic Chemistry (2001), 66(20), 6654-6661
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:357786
IT 372953-56-5P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and evaluation of tetrahydrocyclopropa[c]benz[e]indol-4-one analogs of CC-1065 and the duocarmycins defining the contribution of the DNA-binding domain)
RN 372953-56-5 CAPLUS
CN Carbamic acid, [5-[[[5-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-hydroxy-3H-benz[e]indol-3-yl]carbonyl]-3-thienyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 Jul 2001
GI



I

AB The title compds. [I; X = O, S; R1 = alkyl, cycloalkyl, halo; R2 = H, alkyl, alkoxy, etc.; R3 = alkyl; A = (un)substituted ortho-substituted (hetero)aryl, bicyclo(hetero)aryl] which have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms, were prepared Thus, methylation of Me 4-methylpyrrole-3-carboxylate followed by hydrolysis of the resulting ester, and reaction of 1,4-dimethylpyrrole-3-carboxylic acid with 2-(4'-fluorophenyl)aniline afforded I [X = O; R1, R3 = Me; R2 = H; A = 4'-fluorobiphenyl-2-yl] which showed strong efficacy against Puccinia recondita on wheat (< 20% infestation).
ACCESSION NUMBER: 2001:545661 CAPLUS
DOCUMENT NUMBER: 135:137397
TITLE: Preparation of pyrrolecarboxamides and pyrrolethioamides as fungicides
INVENTOR(S): Walter, Harald; Schneider, Hermann
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053259	A1	20010726	WO 2001-EP592	20010119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2397008	AA	20010726	CA 2001-2397008	20010119
BR 2001007738	A	20021022	BR 2001-7738	20010119
EP 1252140	A1	20021030	EP 2001-907468	20010119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520269	T2	20030702	JP 2001-553263	20010119
AU 772635	B2	20040506	AU 2001-35433	20010119
ZA 2002005641	A	20031103	ZA 2002-5641	20020715
US 2004049035	A1	20040311	US 2002-181702	20021008
US 6806286	B2	20041019		

L10 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 2004106521 A1 20040603 US 2003-680346 20031007
PRIORITY APPLN. INFO.: GB 2000-1447 A 20000121
WO 2001-EP592 W 20010119
US 2002-181702 A3 20021008

OTHER SOURCE(S): MARPAT 135:137397

IT **351416-74-5P 351416-75-6P 351416-76-7P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolecarboxamides and pyrrolethioamides as fungicides)

RN 351416-74-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-chlorophenyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 351416-75-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-chlorophenyl)-3-thienyl]-1-methyl-4-(pentafluoroethyl)- (9CI) (CA INDEX NAME)



RN 351416-76-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-fluorophenyl)-3-thienyl]-1-methyl-4-(pentafluoroethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 Jul 2001
GI



I

AB The title compds. [I; X = O, S; R1 = H, alkyl, halo; R2 = alkyl; A = ortho-substituted aryl, ortho-substituted heteroaryl, bicycloaryl, bicycloheteroaryl] which have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms, were prepared E.g., a multi-step synthesis of I (R1 = H; R2 = Me; X = O; A = 4-(4-chlorophenyl)pyridin-3-yl] which showed strong efficacy against Erypsiphe graminis on barley, was given.

ACCESSION NUMBER: 2001:507677 CAPLUS
DOCUMENT NUMBER: 135:92539
TITLE: Preparation of trifluoromethylpyrrole carboxamides and trifluoromethylpyrrolethioamides as fungicides
INVENTOR(S): Walter, Harald; Trah, Stephan; Schneider, Hermann
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049664	A1	20010712	WO 2000-EP11196	20001111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395267	AA	20010712	CA 2000-2395267	20001111
BR 2000016871	A	20021008	BR 2000-16871	20001111
EP 1252139	A1	20021030	EP 2000-985016	20001111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519212	T2	20030617	JP 2001-550204	20001111
EG 22599	A	20030430	EG 2000-1588	20001224
ZA 2002004874	A	20030918	ZA 2002-4874	20020618
US 6699818	B1	20040302	US 2002-169281	20021008
US 2004171490	A1	20040902	US 2004-785836	20040224

PRIORITY APPLN. INFO.:
GB 1999-30750 A 19991229
WO 2000-EP11196 W 20001111
US 2002-169281 A3 20021008

L10 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

OTHER SOURCE(S): MARPAT 135:92539

IT **349486-95-9P 349486-96-0P 349486-97-1P**
349486-98-2P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of trifluoromethylpyrrole carboxamides and trifluoromethylpyrrolethioamides as fungicides)

RN 349486-95-9 CAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[2-(4-methylcyclohexyl)-3-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349486-96-0 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-isoxazolyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 349486-97-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(3-fluoro-4-pyridinyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 349486-98-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(1,2-dihydro-2-oxo-3-pyridinyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 11 Aug 2000
GI



AB The title compds. [I; X = CH2, SO2; R1 = (un)substituted aryl, heteroaryl; R2 = CO2H, CN, COCH2OH, etc.; R3 = OR15 (wherein R15 = substituted alkyl or cycloalkyl, (un)substituted heteroaryl), S(O)qR15 (q = 0-2), (CH2)sCO2H (s = 0-4), etc.; R4-R7 = H, (un)substituted hydrocarbyl, heterocyclyl, etc.] and their pharmaceutically acceptable salts, amides or esters, useful in the preparation of a medicament for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis, were prepared and formulated. Thus, hydrolysis of the corresponding ester afforded 93% II which showed IC50 of 6.86 μM against hMCP-1 receptor binding.

ACCESSION NUMBER: 2000:553556 CAPLUS
DOCUMENT NUMBER: 133:150463
TITLE: Preparation of 3-substituted indole-2-carboxylic acids for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis
INVENTOR(S): Faull, Alan Wellington; Kettle, Jason
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046199	A2	20000810	WO 2000-GB284	20000131
WO 2000046199	A3	20001130		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,

L10 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2355734	AA	20000810	CA 2000-2355734	20000131
BR 2000008015	A	20011106	BR 2000-8015	20000131
EP 1173421	A2	20020123	EP 2000-901747	20000131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536362	T2	20021029	JP 2000-597270	20000131
ZA 2001005017	A	20020919	ZA 2001-5017	20010619
NO 2001003768	A	20011001	NO 2001-3768	20010801
US 6833387	B1	20041221	US 2001-889516	20011002
PRIORITY APPLN. INFO.:			GB 1999-2455 A	19990205
			WO 2000-GB284 W	20000131

OTHER SOURCE(S): MARPAT 133:150463
IT 287725-88-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-substituted indole-2-carboxylic acids for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis)
RN 287725-88-6 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[(tetrahydro-1,1-dioxido-3-thienyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 287726-47-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-substituted indole-2-carboxylic acids for the inhibition of monocyte chemoattractant protein-1 and/or RANTES induced chemotaxis)
RN 287726-47-0 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[(3,4-dichlorophenyl)methyl]-3-[[(tetrahydro-1,1-dioxido-3-thienyl)amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L10 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Jun 2000
GI



I



II

AB The development of a solution-phase synthesis of distamycin A and its extension to the preparation of 2640 analogs are described. Thus, solution-phase synthesis techniques with reaction workup and purification employing acid/base liquid-liquid extns. were used in the multistep preparation of distamycin A (8 steps, 40% overall yield) and a prototypical library of 2640 analogs providing intermediates and final products that are ≥95% pure on conventional reaction scales. The complementary development of a simple, rapid, and high-throughput screen for DNA binding affinity based on the loss of fluorescence derived from displacement of prebound ethidium bromide is disclosed which is applicable for assessing relative or absolute binding affinity to DNA homopolymers or specific sequences (hairpin oligonucleotides). Using hairpin oligonucleotides, this method permits the screening of a library of compds. against a single predefined sequence to identify high affinity binders, or the screening of a single compound against a full library of individual hairpin oligonucleotides to define its sequence selectivity. The combination permits the establishment of the complete DNA binding profile of each member of a library of compds. Screening the prototypical library provided compds. that are 1000 times more potent than distamycin A in cytotoxic assays (I, Boc = tert-butoxycarbonyl; IC50 = 29 nM, L1210), that bind to poly[dA]-poly[dT] with comparable affinity, and that exhibit an altered DNA binding sequence selectivity. Several candidates were identified which bound the

L10 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
five-base-pair AT-rich site of the PSA-ARE-3 sequence, and one (II, R = 4-dimethylaminobutyryl; K = 3.2 + 106 M-1) maintained the high affinity binding (K = 4.5 + 106 M-1) to the ARE-consensus sequence contg. a GC base-pair interrupted five-base-pair AT-rich site suitable for inhibition of gene transcription initiated by hormone insensitive androgen receptor dimerization and DNA binding characteristic of therapeutic resistant prostate cancer.

ACCESSION NUMBER: 2000:405663 CAPLUS
DOCUMENT NUMBER: 133:223039
TITLE: Total Synthesis of Distamycin A and 2640 Analogs: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity
AUTHOR(S): Boger, Dale L.; Fink, Brian E.; Hedrick, Michael P.
CORPORATE SOURCE: Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA
SOURCE: Journal of the American Chemical Society (2000), 122(27), 6382-6394
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:223039

IT **292069-27-3P 292069-37-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(total synthesis of distamycin A and solution-phase combinatorial approach to distamycin A analogs as DNA binding agents)

RN 292069-27-3 CAPLUS
CN Benzo[1,2-b:4,3-b']dipyrrole-2-carboxylic acid, 6-[[4-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-2-thienyl]carbonyl]-3,6,7,8-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)



RN 292069-37-5 CAPLUS
CN Benzo[1,2-b:4,3-b']dipyrrole-2-carboxylic acid, 6-[[4-[[[4-[[4-

L10 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(dimethylamino)-1-oxobutyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-2-thienyl]carbonyl]-3,6,7,8-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)



IT **292070-05-4P 292071-72-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(total synthesis of distamycin A and solution-phase combinatorial approach to distamycin A analogs as DNA binding agents)

RN 292070-05-4 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 292071-72-8 CAPLUS
CN 2-Thiophenecarboxylic acid, 4-[[[4-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Feb 2000
GI



I

AB Title compds. I (R1 = H, halo, alkyl, haloalkyl; R2 = alkyl, haloalkyl, alkoxyalkyl, cyano, alkylsulfonyl, arylsulfonyl, etc.; A = substituted Ph, substituted 3-thienyl, substituted 4-indanyl) were prepared as plant protectants. Thus, 1.9 g 1-methyl-4-(trifluoromethyl)pyrrole-3-carboxylic acid, obtained from Et 4,4,4-trifluorocrotonate, tosylmethyl isocyanide, and MeI, and 0.9 mL oxalyl chloride in 20 mL CH2Cl2 was stirred at room temperature in the presence of a catalytic amount of DMF, the solvent was evaporated
under reduced pressure to give a crystalline solid, and the solid was added to a solution of 1.7 g of 2-biphenylamine and 4.2 mL Et3N in 20 mL CH2Cl2 at 0°, and the reaction mixture was stirred for 2 h at room temperature to give I (R1 = H, R2 = Me, A = 2-biphenylyl). Application of this compound on apples, grapes, and tomatoes resulted in <10% infestation by Botrytis cinerea.

ACCESSION NUMBER: 2000:133660 CAPLUS
DOCUMENT NUMBER: 132:166122
TITLE: (Trifluoromethyl)pyrrolecarboxamides
INVENTOR(S): Eberle, Martin; Walter, Harald
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009482	A1	20000224	WO 1999-EP5837	19990810
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 576831	B	20040221	TW 1999-88107745	19990513
AU 9955138	A1	20000306	AU 1999-55138	19990810
AU 756140	B2	20030102		
BR 9912962	A	20010508	BR 1999-12962	19990810
EP 1105375	A1	20010613	EP 1999-941573	19990810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100478	T2	20010621	TR 2001-200100478	19990810
JP 2002522526	T2	20020723	JP 2000-564936	19990810
US 2002019541	A1	20020214	US 2001-780897	20010209
US 6365620	B2	20020402		

PRIORITY APPLN. INFO.: GB 1998-17548 A 19980812
WO 1999-EP5837 W 19990810

OTHER SOURCE(S): MARPAT 132:166122
IT **258510-88-2P 258510-89-3P 258510-91-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
((trifluoromethyl)pyrrolecarboxamides as plant protectants)
RN 258510-88-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-fluorophenyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-89-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-chlorophenyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-91-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-biphenyl]-4-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L10 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Sep 1999
GI



I II



III

AB Indole derivs. (I) and (II) [where R1 = H, halogen, CF3, C1-10 alkyl, S-C1-10 alkyl, C1-10 alkoxy, CN, NO2, NH2, Ph, OPh, SPh, CH2Ph, OCH2Ph, SCH2Ph, or (un)substituted amido, carbamido, sulfonyl, etc.; R2 = H, halogen, CF3, OH, C1-10 alkyl, C1-10 alkoxy, CHO, CN, NO2, (un)substituted amino, SO2-C1-6 alkyl; R3 = (un)substituted carboxylic acid, OPO3H2, SO3H, etc.; R4 = H, CF3, C1-6 alkyl, C1-6 alkoxy, (C1-6 alkyl)cycloalkyl, CHO, halogen, etc.; R5 = C1-6 alkyl, C1-6 alkoxy, (C1-6 alkyl)cycloalkyl, etc.] and pharmaceutically acceptable salts thereof, were prepared by several methods. Thus, 5-nitroindole was C3-alkylated with Me 4-(bromomethyl)-3-methoxybenzoate in dioxane, N-alkylated with 1-iodopropane in a solution of THF and NaH, and converted to the amine by hydrogenation over Pt/C. The amine was converted to the carbamate by addition of cyclopentyl chloroformate in CH2Cl2 and 4-methylmorpholine and the resultant ester hydrolyzed to yield 4-[(5-[[(cyclopentyloxy)carbonyl]amino]-1-propyl-1H-indol-3-yl)methyl]-3-methoxybenzoic acid (III). The title compds. are useful as phospholipase enzyme inhibitors, especially cytosolic phospholipase A2 (cPLA2), for treatment of inflammatory conditions, particularly where inhibition of production of prostaglandins, leukotrienes, and PAF are all desired. Over one hundred compds. of the invention were tested for cPLA2 inhibiting activity in the Coumarine assay and rat carrageenan-induced footpad edema test. Compds. exhibited 7% to 98% inhibition at concns. of 0.125 μM to 400 μM in the Coumarine assay and -7.16% to 34.52% inhibition at concns. of 2 μM to 20 μM in the footpad edema test.

ACCESSION NUMBER: 1999:566026 CAPLUS
DOCUMENT NUMBER: 131:199619
TITLE: Preparation of indole derivatives as phospholipase enzyme inhibitors
INVENTOR(S): Seehra, Jasbir S.; Mckew, John C.; Lovering, Frank; Bemis, Jean E.; Xiang, Yibin; Chen, Lihren; Knopf, John L.
PATENT ASSIGNEE(S): Genetics Institute, Inc., USA
SOURCE: PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

L10 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943654	A2	19990902	WO 1999-US3898	19990224
WO 9943654	A3	19991028		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2322162	AA	19990902	CA 1999-2322162	19990224
AU 9927825	A1	19990915	AU 1999-27825	19990224
AU 765427	B2	20030918		
BR 9908275	A	20001024	BR 1999-8275	19990224
TR 200002447	T2	20001121	TR 2000-200002447	19990224
EP 1062205	A2	20001227	EP 1999-908378	19990224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002504541	T2	20020212	JP 2000-533412	19990224
EE 200000488	A	20020215	EE 2000-488	19990224
NZ 506329	A	20040130	NZ 1999-506329	19990224
NO 2000004219	A	20001023	NO 2000-4219	20000823
HR 2000000551	A1	20010430	HR 2000-551	20000824
BG 104779	A	20011031	BG 2000-104779	20000919
PRIORITY APPLN. INFO.:			US 1998-30592 A	19980225
			WO 1999-US3898 W	19990224

OTHER SOURCE(S): MARPAT 131:199619
IT **241497-74-5DP**, ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indole derivs. as phospholipase enzyme inhibitors for treatment of inflammatory conditions)
RN 241497-74-5 CAPLUS
CN 3-Thiophenecarboxylic acid, 4-[[[5-[(cyclopentylcarbonyl)amino]-1-(diphenylmethyl)-1H-indol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT **241497-74-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as phospholipase enzyme inhibitors for treatment of inflammatory conditions)

L10 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 241497-74-5 CAPLUS
CN 3-Thiophenecarboxylic acid, 4-[[[5-[(cyclopentylcarbonyl)amino]-1-(diphenylmethyl)-1H-indol-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



L10 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 03 Sep 1994
GI



I

AB Title compds. I (R1 = MeCHMe, MeCHF, HOCH2; R2 = H, C1-4 alkyl; Z = HO2C, HO3S, tetrazol-5-yl, C1-4alkyl-SO2NHCO; A = (substituted)Ph or thienyl) a pharmaceutically acceptable salt or in vivo hydrolyzable ester thereof, are prepared 2-Thiophenecarboxylic acid was nitated to give the 4-nitro derivative, reduced ti the 4-amino derivative converted to the (2S,4S)-1-(4-nitrobenzylcarbonyl)-2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthioacetate which in in 4 steps was converted to (5R,6S,8R,2'S,4'S)-I (R1 = MeCHOH, R2 = H, A = 4-thienyl, Z = 2-HO2C) which had a min. inhibitory concentration of 0.5 mg/mL against Enterobacter cloacae 108 vs 32 mg/L of ceftriaxone. Pharmaceutical formulations comprising I are given.
ACCESSION NUMBER: 1994:508368 CAPLUS
DOCUMENT NUMBER: 121:108368
TITLE: Preparation of antibiotic pyrrolidinylthiopenem derivatives
INVENTOR(S): Siret, Patrice Jean
PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 592167	A1	19940413	EP 1993-307843	19931001
EP 592167	B1	19991222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2106330	AA	19940408	CA 1993-2106330	19930916
AT 187968	E	20000115	AT 1993-307843	19931001
ES 2140445	T3	20000301	ES 1993-307843	19931001
JP 06211871	A2	19940802	JP 1993-250437	19931006
US 5538962	A	19960723	US 1993-132256	19931006
PRIORITY APPLN. INFO.:			EP 1992-402733 A	19921007

OTHER SOURCE(S): MARPAT 121:108368
IT **155481-27-9P 155481-28-0P 156631-41-3P 156631-42-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antibiotics)
RN 155481-27-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[(5-carboxy-3-thienyl)amino]carbonyl]-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155481-28-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(5-carboxy-3-thienyl)amino]carbonyl]-4-mercapto-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156631-41-3 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[[[5-[(2-propenyloxy)carbonyl]-3-thienyl]amino]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, 2-propenyl ester, [5R-[3(3S*,5S*),5α,6α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156631-42-4 CAPLUS

L10 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[[[5-[(2-propenyloxy)carbonyl]-3-thienyl]amino]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, 2-propenyl ester, [5R-[3(3S*,5S*),5α,6α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Jul 1994
GI



AB Title compds. I (R = (un)substituted carboxythienyl; R1 = CHMeOH, CHMeF, CH2OH; R2, R3 = H, alkyl) were prepared Thus, the carbapenem II was obtained from the diphenylphosphoryloxycarbapenem and the thiol, prepared from 2-thiophenecarboxylic acid and the protected mercaptopyrrolidinecarboxylic acid in 4 steps. II had min. inhibitory concns. against Staphylococcus aureus Oxford 0.125 and Escherichia coli DC0 0.008 μg/mL.

ACCESSION NUMBER: 1994:409029 CAPLUS
DOCUMENT NUMBER: 121:9029
TITLE: Carbapenem derivatives as antibiotics and intermediates thereof
INVENTOR(S): Jung, Frederic Henri
PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S. A.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319070	A1	19930930	WO 1993-GB603	19930324
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KZ, LK, LU, MG, NL, NO, PL, RO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
ZA 9301611	A	19930927	ZA 1993-1611	19930305
IL 105135	A1	20000131	IL 1993-105135	19930323
AU 9337636	A1	19931021	AU 1993-37636	19930324
AU 662972	B2	19950921		
EP 586663	A1	19940316	EP 1993-906740	19930324
EP 586663	B1	19990929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 65713	A2	19940728	HU 1993-3304	19930324
JP 06508372	T2	19940922	JP 1993-516398	19930324
JP 3313366	B2	20020812		

L10 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AT 185140	E	19991015	AT 1993-906740	19930324
ES 2136124	T3	19991116	ES 1993-906740	19930324
CA 2108356	C	20040120	CA 1993-2108356	19930324
CN 1077957	A	19931103	CN 1993-102800	19930326
CN 1036713	B	19971217		
NO 9304264	A	19931125	NO 1993-4264	19931125
FI 104075	B1	19991115	FI 1993-5245	19931125
US 5519015	A	19960521	US 1993-142459	19931126

PRIORITY APPLN. INFO.: EP 1992-400836 A 19920326
EP 1992-402763 A 19921009
WO 1993-GB603 A 19930324

OTHER SOURCE(S): MARPAT 121:9029
IT **155481-26-8P 155481-27-9P 155481-28-0P**
155481-30-4P 155481-31-5P 155481-32-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of carboxythienylcarbamoylpyrrolidinylthiocarbapenemcarboxylates)
RN 155481-26-8 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(5-carboxy-3-thienyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, 2-[(4-nitrophenyl)methyl] ester, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 155481-25-7
CMF C35 H33 N5 O13 S2



CM 2

CRN 7087-68-5
CMF C8 H19 N



RN 155481-27-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[(5-carboxy-3-thienyl)amino]carbonyl]-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 155481-28-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(5-carboxy-3-thienyl)amino]carbonyl]-4-mercapto-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155481-30-4 CAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(2-carboxy-3-thienyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, 2-(2-propenyl) ester, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 155481-29-1
CMF C31 H32 N4 O11 S2

Absolute stereochemistry.

L10 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 7087-68-5
CMF C8 H19 N



RN 155481-31-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[(2-carboxy-3-thienyl)amino]carbonyl]-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155481-32-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-mercapto-2-[(3-thienylamino)carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L10 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 29 Nov 1991
GI



AB Title compds. I [R = 5- or 6-membered (monohydroxylated) (O- or S-containing) saturated cyclic amino, Q, Q1], useful for treatment of amnesia and dementia, are prepared Treatment of carbobenzoxy-L-pyroglutamic acid with thiazolidine, 1-hydroxybenztriazole.H2O, and DCC in MeCN at room temperature for 14 h gave N-(1-benzyloxycarbonyl-5-oxo-L-prolyl)thiazolidine, which inhibited prolyl endopeptidase with IC50 of 0.32 μM.

ACCESSION NUMBER: 1991:632874 CAPLUS
DOCUMENT NUMBER: 115:232874
TITLE: Preparation of pyroglutamic acid amides as prolyl endopeptidase inhibitors
INVENTOR(S): Furukawa, Atsushi; Yoshimoto, Tadashi; Tsuru, Onori; Ajisawa, Yukiyoshi; Kinoshita, Yukihiko
PATENT ASSIGNEE(S): Kissei Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03056461	A2	19910312	JP 1989-190747	19890724
JP 07103101	B4	19951108		
PRIORITY APPLN. INFO.:			JP 1989-190747	19890724

OTHER SOURCE(S): MARPAT 115:232874
IT 137042-90-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as prolyl endopeptidase inhibitor)
RN 137042-90-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-oxo-5-[[(tetrahydro-2-oxo-3-thienyl)amino]carbonyl]-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



Ngrazier 10680346search

```
=> s l6
L11           2 L6

=> d ed abs ibib hitstr 1-2
```

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 Jul 2001
GI



I

AB The title compds. [I; X = O, S; R1 = alkyl, cycloalkyl, halo; R2 = H, alkyl, alkoxy, etc.; R3 = alkyl; A = (un)substituted ortho-substituted (hetero)aryl, bicyclo(hetero)aryl] which have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms, were prepared Thus, methylation of Me 4-methylpyrrole-3-carboxylate followed by hydrolysis of the resulting ester, and reaction of 1,4-dimethylpyrrole-3-carboxylic acid with 2-(4'-fluorophenyl)aniline afforded I [X = O; R1, R3 = Me; R2 = H; A = 4'-fluorobiphenyl-2-yl] which showed strong efficacy against Puccinia recondita on wheat (< 20% infestation).
ACCESSION NUMBER: 2001:545661 CAPLUS
DOCUMENT NUMBER: 135:137397
TITLE: Preparation of pyrrolecarboxamides and pyrrolethioamides as fungicides
INVENTOR(S): Walter, Harald; Schneider, Hermann
PATENT ASSIGNEE(S): Syngenta Participations A.-G., Switz.
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053259	A1	20010726	WO 2001-EP592	20010119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2397008	AA	20010726	CA 2001-2397008	20010119
BR 2001007738	A	20021022	BR 2001-7738	20010119
EP 1252140	A1	20021030	EP 2001-907468	20010119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003520269	T2	20030702	JP 2001-553263	20010119
AU 772635	B2	20040506	AU 2001-35433	20010119
ZA 2002005641	A	20031103	ZA 2002-5641	20020715

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

US 2004049035	A1	20040311	US 2002-181702	20021008
US 6806286	B2	20041019		
US 2004106521	A1	20040603	US 2003-680346	20031007
PRIORITY APPLN. INFO.:			GB 2000-1447	A 20000121
			WO 2001-EP592	W 20010119
			US 2002-181702	A3 20021008

OTHER SOURCE(S): MARPAT 135:137397
IT **351416-74-5P 351416-75-6P 351416-76-7P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolecarboxamides and pyrrolethioamides as fungicides)
RN 351416-74-5 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-chlorophenyl)-3-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 351416-75-6 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-chlorophenyl)-3-thienyl]-1-methyl-4-(pentafluoroethyl)- (9CI) (CA INDEX NAME)



RN 351416-76-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-fluorophenyl)-3-thienyl]-1-methyl-4-(pentafluoroethyl)- (9CI) (CA INDEX NAME)

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 25 Feb 2000
GI



I

AB Title compds. I (R1 = H, halo, alkyl, haloalkyl; R2 = alkyl, haloalkyl, alkoxyalkyl, cyano, alkylsulfonyl, arylsulfonyl, etc.; A = substituted Ph, substituted 3-thienyl, substituted 4-indanyl) were prepared as plant protectants. Thus, 1.9 g 1-methyl-4-(trifluoromethyl)pyrrole-3-carboxylic acid, obtained from Et 4,4,4-trifluorocrotonate, tosylmethyl isocyanide, and MeI, and 0.9 mL oxalyl chloride in 20 mL CH2Cl2 was stirred at room temperature in the presence of a catalytic amount of DMF, the solvent was evaporated
under reduced pressure to give a crystalline solid, and the solid was added to a solution of 1.7 g of 2-biphenylamine and 4.2 mL Et3N in 20 mL CH2Cl2 at 0°, and the reaction mixture was stirred for 2 h at room temperature to give I (R1 = H, R2 = Me, A = 2-biphenylyl). Application of this compound on apples, grapes, and tomatoes resulted in <10% infestation by Botrytis cinerea.
ACCESSION NUMBER: 2000:133660 CAPLUS
DOCUMENT NUMBER: 132:166122
TITLE: (Trifluoromethyl)pyrrolecarboxamides
INVENTOR(S): Eberle, Martin; Walter, Harald
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009482	A1	20000224	WO 1999-EP5837	19990810
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 576831	B	20040221	TW 1999-88107745	19990513
AU 9955138	A1	20000306	AU 1999-55138	19990810
AU 756140	B2	20030102		
BR 9912962	A	20010508	BR 1999-12962	19990810
EP 1105375	A1	20010613	EP 1999-941573	19990810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100478	T2	20010621	TR 2001-200100478	19990810

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

JP 2002522526	T2	20020723	JP 2000-564936		19990810
US 2002019541	A1	20020214	US 2001-780897		20010209
US 6365620	B2	20020402			
PRIORITY APPLN. INFO.:			GB 1998-17548	A	19980812
			WO 1999-EP5837	W	19990810

OTHER SOURCE(S): MARPAT 132:166122

IT **258510-88-2P 258510-89-3P 258510-91-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
((trifluoromethyl)pyrrolecarboxamides as plant protectants)

RN 258510-88-2 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-fluorophenyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-89-3 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[2-(4-chlorophenyl)-3-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 258510-91-7 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(2-[1,1'-biphenyl]-4-yl-3-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L11 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10680346search

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	124.40	612.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-18.25	-18.25

STN INTERNATIONAL LOGOFF AT 12:06:27 ON 30 AUG 2005





chain nodes :
6 7 8 10 11 12
ring nodes :
1 2 3 4 5
chain bonds :
1-10 6-7 6-8 7-11 7-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-12

G1:H,CH3

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS
Generic attributes :
11:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

Ngrazier 10680346expA2A3A4A6A9



G1 H,Me

G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:44:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 136055 TO ITERATE

1.5% PROCESSED 2000 ITERATIONS 7 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2699331 TO 2742869
PROJECTED ANSWERS: 8214 TO 10832

L2 7 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10680346exp2.str





chain nodes :
6 7 8 10 11 12
ring nodes :
1 2 3 4 5
chain bonds :
1-10 6-7 6-8 7-11 7-12
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-12

G1:H,CH3

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:CLASS
Generic attributes :
11:
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : less than 2
Type of Ring System : Monocyclic

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 H,Me

G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l3
SAMPLE SEARCH INITIATED 13:46:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 136055 TO ITERATE

1.5% PROCESSED 2000 ITERATIONS 7 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2699331 TO 2742869
PROJECTED ANSWERS: 8214 TO 10832

L4 7 SEA SSS SAM L3

=>

Ngrazier 10680346expA2A3A4A6A9

Uploading C:\Program Files\Stnexp\Queries\346ep2.str





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 15 16 17 18
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-15 14-18 15-16 16-17 17-18
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-15 14-18 15-16 16-17 17-18

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 13:52:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1828 TO ITERATE

100.0% PROCESSED     1828 ITERATIONS                              11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        33996 TO    39124
PROJECTED ANSWERS:              22 TO      418

L6            11 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 13:52:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  37137 TO ITERATE

100.0% PROCESSED    37137 ITERATIONS                             294 ANSWERS
SEARCH TIME: 00.00.01

L7           294 SEA SSS FUL L5

=> fil hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   166.92     167.13

FILE 'HCAPLUS' ENTERED AT 13:52:44 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 30 Aug 2005 VOL 143 ISS 10
FILE LAST UPDATED: 29 Aug 2005 (20050829/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l7
L8 41 L7

=> d ed abs ibib hitstr 1-41

L8 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 May 2005
GI



I



II

AB Title compds. I [wherein R1 = (un)substituted (C3-7 cycloalkyl)methyl, hetero/aryl; R2 = H, NO2, CN, CO2H and derivs., NH2 and derivs., etc.; R3 = (un)substituted hetero/aryl; and their pharmaceutically acceptable salts] were prepared as p38 MAP kinase inhibitors for treating and/or preventing immune or inflammatory disorders. For example, II was prepared by reacting Et 3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate (preparation given) with 3-methylbenzaldehyde and oxidation with MnO2.
I are potent inhibitors of p38 MAP kinase (IC50 around 2 μM and below), especially p38α kinase.

ACCESSION NUMBER: 2005:409526 HCAPLUS
DOCUMENT NUMBER: 142:463710
TITLE: Preparation of thieno[2,3-b]pyridinone derivatives as kinase, especially p38 MAP kinase, inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders
INVENTOR(S): Alexander, Rikki Peter; Davis, Jeremy Martin; Hutchings, Martin Clive; Laing, Victoria Elizabeth; Trevitt, Graham Peter
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 181 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

L8 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042540	A1	20050512	WO 2004-GB4490	20041022

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	GB 2003-24902	A 20031024
	GB 2003-29490	A 20031219
	GB 2004-2918	A 20040210
	GB 2004-16934	A 20040729

OTHER SOURCE(S): MARPAT 142:463710
IT **851749-00-3P**, tert-Butyl (2S)-2-[[(3-benzoyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)amino]carbonyl]pyrrolidine-1-carboxylate
851749-02-5P, tert-Butyl (2R)-2-[[(3-benzoyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)amino]carbonyl]pyrrolidine-1-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of thienopyridinones as p38 MAP kinase inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders)
RN 851749-00-3 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(3-benzoyl-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)amino]carbonyl]-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851749-02-5 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(3-benzoyl-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)amino]carbonyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **851753-37-2P**, N-(3-Benzoyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)-1-methyl-2-pyrrolidinecarboxamide **851753-40-7P**, N-(3-Benzoyl-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)-1-methyl-D-prolinamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(p38α kinase inhibitor; preparation of thienopyridinones as p38 MAP kinase inhibitors useful in the treatment of and/or prevention of immune or inflammatory disorders)
RN 851753-37-2 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-(3-benzoyl-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)-1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851753-40-7 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-(3-benzoyl-6,7-dihydro-6-oxo-7-phenylthieno[2,3-b]pyridin-2-yl)-1-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 1 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 06 Aug 2004
GI



I

II



III

AB Condensed pyridines and pyrimidines (quinolines, quinazolines and thienopyrimidines) of formula I [X is N or CH; Y is -NR- or -NHCH2-; R is alkyl; A is a fused 5-7 membered carbocyclic or N/O/S-heterocyclic ring with one or more R1 groups; R1 is H, halo, NO2, alkyl, OR, CONR4R5, O(CH2)nNR4R5, (CH2)nNR4R5, or NR4R5; R2 is certain N-containing heterocyclic rings; R3 is pyridin-2-yl, C1-6alkyl-pyridin-2-yl, -pyrrol-2-yl or -thiazol-2-yl; R4 is H or alkyl; R5 is alkyl; NR4R5 can be 3-7 membered (un)saturated N/O/S-heterocycle] and their pharmaceutically acceptable salts, solvates or derivs. were synthesized. Thus, 2-aminobenzamide was coupled with 6-methyl-2-pyridinecarboxylic acid in the presence of EDCI/HOBT followed by cyclocondensation mediated by NaOH to give quinazolinone II. Chlorination of II with POCl3 and subsequent substitution of the resulting chloride with 4-aminopyridine afforded quinazoline III. These compds. are inhibitors of the transforming growth factor TGF-β, especially of activin-like kinase ALK-5 receptor, and are used in the treatment and prevention of various disease states mediated by ALK-5 kinase mechanisms such as kidney fibrosis. All the final products showed ALK5 receptor modulator activity with IC50 of 1-200 nM (16 nM for III) and TGF-β cellular activity with IC50 of 0.001-10 μM (82 nM for III). The role of ALK5 inhibitors for the treatment of photoaging was also demonstrated exptl.

ACCESSION NUMBER: 2004:633933 HCAPLUS
DOCUMENT NUMBER: 141:174181
TITLE: Preparation of quinolines, quinazolines and thienopyrimidines as ALK-5 receptor ligands for the treatment of kidney fibrosis
INVENTOR(S): Dodic, Nerina; Gellibert, Francoise Jeanne; Hunter, Robert Neil, III
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065392	A1	20040805	WO 2004-EP650	20040126
WO 2004065392	C1	20041007		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

PRIORITY APPLN. INFO.:	GB 2003-1719	A 20030124
	GB 2003-8706	A 20030415
	GB 2003-15519	A 20030702

OTHER SOURCE(S): MARPAT 141:174181

IT **733806-35-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinolines, quinazolines and thienopyrimidines as ALK-5 receptor ligands for the treatment of, e.g., kidney fibrosis)

RN 733806-35-4 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(aminocarbonyl)-4-methyl-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Jul 2004
AB Hairpin polyamides are synthetic oligomers, which fold and bind to specific DNA sequences in a programmable manner. Internal side-by-side pairings of the aromatic amino acid residues 1-methyl-1H-pyrrole (Py), 1-methyl-1H-imidazole (Im), and 3-hydroxy-1-methyl-1H-pyrrole (Hp) confer the ability to distinguish between all 4 Watson-Crick base pairs in the minor groove of B-form DNA. In a broad search to expand the heterocycle repertoire, we found that when 3-methylthiophene (Tn), which presents a S-atom to the minor groove, is paired with Py, it exhibits a modest 3-fold specificity for T·A > A·T, presumably by shape-selective recognition. In this study, we explore the scope and limitations of this lead by incorporating multiple Tn residues within a single hairpin polyamide. Hairpin polyamides containing >1 Tn/Py pair exhibit lowered affinities and specificities for their match sites. It appears that little deviation is permissible from the parent 5-membered ring 1-methyl-1H-pyrrole-2-carboxamide scaffold for DNA recognition.

ACCESSION NUMBER: 2004:573249 HCAPLUS
DOCUMENT NUMBER: 141:407378
TITLE: DNA minor-groove recognition by 3-methylthiophene/pyrrole pair
AUTHOR(S): Doss, Raymond M.; Marques, Michael A.; Foister, Shane; Dervan, Peter B.
CORPORATE SOURCE: Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, 91125, USA
SOURCE: Chemistry & Biodiversity (2004), 1(6), 886-899
CODEN: CBHIAM; ISSN: 1612-1872
PUBLISHER: Verlag Helvetica Chimica Acta AG
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **791626-78-3P**
RL: ARG (Analytical reagent use); CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); PROC (Process); USES (Uses)
(DNA minor-groove recognition by 3-methylthiophene/pyrrole pair)

RN 791626-78-3 HCAPLUS
CN 1H-Imidazole-2-carboxamide, N-[5-[[[5-[[[5-[[[3-[[3-(dimethylamino)propyl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-4-methyl-2-thienyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-4-[[4-[[[1-methyl-4-[[[3-methyl-5-[[[1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-2-thienyl]carbonyl]amino]-1H-pyrrol-2-yl)carbonyl]amino]-1-oxobutyl]amino]-(9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



IT **791626-83-0P 791626-84-1P 791626-85-2P**
RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(DNA minor-groove recognition by 3-methylthiophene/pyrrole pair)

RN 791626-83-0 HCAPLUS
CN 2-Thiophenecarboxylic acid, 3-methyl-5-[[(1-methyl-4-nitro-1H-pyrrol-2-

L8 ANSWER 3 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
yl)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 791626-84-1 HCAPLUS
CN 2-Thiophenecarboxylic acid, 5-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 791626-85-2 HCAPLUS
CN 2-Thiophenecarboxylic acid, 5-[[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 May 2004
GI



AB A fungicidally active compound I, II, or III [wherein Het = (un)substituted 5- or 6-membered heterocyclic ring containing one to three O, N, and/or S atoms, provided that the ring is not 1,2,3-triazole; R1 and R2 = independently H, halo, or Me; R3 = (un)substituted (cyclo)alkyl, alkenyl, alkynyl, Ph, heterocyclyl; R7 and R8 = independently H, halo, or (halo)alkyl] were prepared for use as active ingredients in agricultural or horticultural comps. for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi. For example, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid was amidated with [2-(bicyclopropyl-2-yl)thiophen-3-yl]amine in the presence of TEA and N,N-bis(2-oxooxazolidinyl)phosphinic acid chloride in CH2Cl2 to give trans-IV (97% purity). The latter showed excellent activity against Puccinia recondita on wheat (0-5% infestation) and showed good activity against Podosphaera leucotricha on apple, Venturia inaequalis on apple, Erysiphe graminis on barley, Pyrenophora teres on barley, Alternaria solani on tomato, and Uncinula necator on grape (<20% infestation for each).

ACCESSION NUMBER: 2004:390242 HCAPLUS
DOCUMENT NUMBER: 140:406731
TITLE: Preparation of N-(cyclopropylthienyl)carboxamides as fungicides
INVENTOR(S): Ehrenfreund, Josef; Tobler, Hans; Walter, Harald
PATENT ASSIGNEE(S): Syngenta Participations Ag, Switz.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039799	A1	20040513	WO 2003-EP11805	20031024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501739	AA	20040513	CA 2003-2501739	20031024
EP 1556377	A1	20050727	EP 2003-776869	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: GB 2002-25554 A 20021101
WO 2003-EP11805 W 20031024

OTHER SOURCE(S): MARPAT 140:406731

IT 688324-04-1P 688324-05-2P 688324-06-3P
688324-07-4P 688324-08-5P 688324-09-6P
688324-10-9P 688324-11-0P 688324-12-1P
688324-13-2P 688324-14-3P 688324-15-4P
688324-16-5P 688324-17-6P 688324-18-7P
688324-19-8P 688324-20-1P 688324-21-2P
688324-22-3P 688324-23-4P 688324-24-5P
688324-25-6P 688324-26-7P 688324-27-8P
688324-28-9P 688324-29-0P 688324-30-3P
688324-31-4P 688324-32-5P 688324-33-6P
688324-34-7P 688324-35-8P 688324-36-9P
688324-37-0P 688324-38-1P 688324-39-2P
688324-40-5P 688324-41-6P 688324-42-7P
688324-43-8P 688324-44-9P 688324-45-0P
688324-47-2P 688324-48-3P 688324-49-4P
688324-50-7P 688324-51-8P 688324-52-9P
688324-53-0P 688324-54-1P 688324-55-2P
688324-56-3P 688324-57-4P 688324-58-5P
688324-59-6P 688324-60-9P 688324-61-0P
688324-62-1P 688324-63-2P 688324-64-3P
688324-65-4P 688324-66-5P 688324-67-6P
688324-68-7P 688324-69-8P 688324-70-1P
688324-71-2P 688324-72-3P 688324-73-4P
688324-74-5P 688324-75-6P 688324-76-7P
688324-77-8P 688324-78-9P 688324-79-0P
688324-80-3P 688324-81-4P 688324-82-5P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fungicide; preparation of N-(cyclopropylthienyl)carboxamides as fungicides)

RN 688324-04-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-ethylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-05-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-ethylcyclopropyl)-2-thienyl]-1-(methoxymethyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-06-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-(2-propylcyclopropyl)-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-07-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[3-(2-propylcyclopropyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-08-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-09-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-10-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-11-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-12-1 HCAPLUS

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1-ethyl-4-methyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-13-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-14-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-ethyl-2-fluoro-4-methyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-15-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-2-fluoro-1-methyl-N-[3-[2-(1-methylethyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-16-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-butylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-17-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-butylcyclopropyl)-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-18-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-butylcyclopropyl)-2-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-19-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-butylcyclopropyl)-2-thienyl]-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-20-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-[2-(2-methylpropyl)cyclopropyl]-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-21-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[3-[2-(2-methylpropyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-22-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[3-[2-(2-methylpropyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-23-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-(methoxymethyl)-N-[3-[2-(2-methylpropyl)cyclopropyl]-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-24-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[3-[2-(2-methylpropyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-25-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[3-[2-(2-methylpropyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-26-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(1,1-dimethylethyl)cyclopropyl]-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-31-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-(2-pentylcyclopropyl)-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-32-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-[2-(3-methylbutyl)cyclopropyl]-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-33-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[3-[2-(3-methylbutyl)cyclopropyl]-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-34-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-hexylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 688324-27-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[3-[2-(1,1-dimethylethyl)cyclopropyl]-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-28-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(1,1-dimethylethyl)cyclopropyl]-2-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-29-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[3-[2-(1,1-dimethylethyl)cyclopropyl]-2-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-30-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[3-[2-(1,1-dimethylethyl)cyclopropyl]-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-35-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-[1,1'-bicyclopropyl]-2-yl-2-thienyl)-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-36-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-[1,1'-bicyclopropyl]-2-yl-2-thienyl)-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-37-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-[1,1'-bicyclopropyl]-2-yl-2-thienyl)-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-38-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-(3-[1,1'-bicyclopropyl]-2-yl-2-thienyl)-2-chloro-1,4-dimethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-39-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclobutylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-40-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclobutylcyclopropyl)-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-41-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclopentylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-42-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclopentylcyclopropyl)-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-43-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclopentylcyclopropyl)-2-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-44-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[3-(2-

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
cyclopentylcyclopropyl)-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-45-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclopentylcyclopropyl)-2-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-47-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[3-(2-cyclopentylcyclopropyl)-2-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-48-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclohexylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-49-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclohexylcyclopropyl)-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-50-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclohexylcyclopropyl)-2-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-51-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[3-(2-cyclohexylcyclopropyl)-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-52-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(3-cyclohexyl-2,2-difluorocyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-53-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclohexylcyclopropyl)-2-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-54-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[3-(2-cyclohexylcyclopropyl)-2-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-55-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cycloheptylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-56-3 HCAPLUS

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cycloheptylcyclopropyl)-2-thienyl]-1-ethyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-57-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cycloheptylcyclopropyl)-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-58-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cycloheptylcyclopropyl)-2-thienyl]-4-(fluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-59-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(chlorodifluoromethyl)-N-[3-(2-cycloheptylcyclopropyl)-2-thienyl]-2-fluoro-1-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-60-9 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cycloheptylcyclopropyl)-2-thienyl]-2-fluoro-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-61-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-N-[3-(2-cycloheptylcyclopropyl)-2-thienyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 688324-62-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclooctylcyclopropyl)-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-63-2 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-(2-cyclooctylcyclopropyl)-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-64-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-(2-phenylcyclopropyl)-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-65-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[3-(2-phenylcyclopropyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-66-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(fluoromethyl)-1-methyl-N-[3-(2-phenylcyclopropyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-67-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[3-(2-phenylcyclopropyl)-2-thienyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-68-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[3-(2-phenylcyclopropyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-69-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(4-fluorophenyl)cyclopropyl]-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-70-1 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-N-[3-[2-(4-fluorophenyl)cyclopropyl]-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-71-2 HCAPLUS

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 688324-75-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-[2-(2-thienyl)cyclopropyl]-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-76-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-[2-(3-thienyl)cyclopropyl]-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-77-8 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(2-furanyl)cyclopropyl]-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-78-9 HCAPLUS

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(4-chlorophenyl)cyclopropyl]-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-72-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(4-chlorophenyl)cyclopropyl]-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 688324-73-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(4-bromophenyl)cyclopropyl]-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-74-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(4-bromophenyl)cyclopropyl]-2-thienyl]-4-(difluoromethyl)-1-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-3-carboxamide, N-[3-[2-(3-furanyl)cyclopropyl]-2-thienyl]-1-methyl-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-79-0 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 1-methyl-N-[3-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-2-thienyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 688324-80-3 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 4-(difluoromethyl)-1-methyl-N-[3-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 688324-81-4 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-fluoro-1,4-dimethyl-N-[3-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-2-thienyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 688324-82-5 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 2-chloro-1,4-dimethyl-N-[3-(1'-methyl[1,1'-bicyclopropyl]-2-yl)-2-thienyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Mar 2004
AB Forty-eight heterocyclic amino acid trimers, analogs of distamycin, with a number of features that enhance lipophilicity are described. They contain alkyl or cycloalkyl groups larger than methyl; some are N-terminated by acetamide or methoxybenzamide and are C-terminated by dimethylaminopropyl or aliphatic heterocyclic aminopropyl substituents. The ability of these compds. to bind principally to AT tracts of DNA has been evaluated using capillary zone electrophoresis. Significant antimicrobial activity against key organisms such as MRSA and Candida albicans is shown by several compds., especially those containing a thiazole. Moreover, these compds. have low toxicity with respect to several mammalian cell lines.
ACCESSION NUMBER: 2004:178994 HCAPLUS
DOCUMENT NUMBER: 140:375474
TITLE: Distamycin Analogues with Enhanced Lipophilicity: Synthesis and Antimicrobial Activity
AUTHOR(S): Khalaf, Abedawn I.; Waigh, Roger D.; Drummond, Allan J.; Pringle, Breffni; McGroarty, Ian; Skellern, Graham G.; Suckling, Colin J.
CORPORATE SOURCE: Department of Pure Applied Chemistry and Department of Pharmaceutical Sciences, University of Strathclyde, Glasgow, G1 1XL, UK
SOURCE: Journal of Medicinal Chemistry (2004), 47(8), 2133-2156
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **683815-40-9P 683815-41-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, antimicrobial and antifungal activities of heterocyclic amino acid trimers as distamycin analogs with enhanced lipophilicity)
RN 683815-40-9 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[4-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-5-methyl-2-thienyl]-4-(formylamino)-1-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 683815-41-0 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(acetylamino)-N-[4-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-5-methyl-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



IT **683815-68-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, antimicrobial and antifungal activities of heterocyclic amino acid trimers as distamycin analogs with enhanced lipophilicity)
RN 683815-68-1 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[4-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-5-methyl-2-thienyl]-1-methyl-4-nitro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Sep 2003
AB The eight novel polyamides: PyPyPyβDp, ImPypPyβDp, ImImPyβDp, PyImImβDp, ImImImβDp, PyPyImβDp, ImPyImβDp, and PyImPyβDp (Py = N-methylpyrrole, Im = N-methylimidazole, β = β-alanine, Dp = N,N-dimethylpropyldiamine) were synthesized by the dicyclohexylcarbodiimide/1-hydroxybenzotriazole (DCC/HOBt) coupling reaction. This paper describes the mass spectral fragmentation mechanisms of these eight polyamides, investigated by electrospray ionization with tandem mass spectrometry (ESI-MS/MS).
ACCESSION NUMBER: 2003:684284 HCAPLUS
DOCUMENT NUMBER: 140:128669
TITLE: Fragmentation mechanisms of polyamides containing N-methylpyrrole and N-methylimidazole by electrospray ionization tandem mass spectrometry
AUTHOR(S): Yuan, Gu; Tang, Feili; Zhu, Chang Jin; Liu, Yan; Zhao, Yu Fen
CORPORATE SOURCE: Department of Chemical Biology, The Key Laboratory of Bioorganic Chemistry and Molecular Engineering, Ministry of Education, College of Chemistry, Peking University, Beijing, 100871, Peop. Rep. China
SOURCE: Rapid Communications in Mass Spectrometry (2003), 17(17), 2015-2018
CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **648928-24-9P 648928-25-0P 648928-29-4P**
RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(fragmentation mechanisms of polyamides containing methylpyrrole and methylimidazole by electrospray ionization tandem mass spectrometry)
RN 648928-24-9 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[[3-[[3-(dimethylamino)propyl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-5-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 648928-25-0 HCAPLUS
CN 1H-Imidazole-2-carboxamide, N-[5-[[[5-[[[3-[[3-(dimethylamino)propyl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 648928-29-4 HCAPLUS
CN 1H-Imidazole-2-carboxamide, N-[3-[[3-(dimethylamino)propyl]amino]-3-oxopropyl]-1-methyl-5-[[[1-methyl-5-[[[1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Mar 2002
GI



I

AB The title compds. I [ring A = (un)substituted heterocyclic ring, etc.; X = bond, O, CO, etc.; ring B = Q1, etc.; ring V3 = hydrocarbon ring, etc.; W = CH, N; Y = CO, etc.; R21, R22 = H, halo, etc.; T1 = (CH2)n; n = 0 - 2; ring D = (un)substituted aryl, etc.] are prepared In an in vitro test (for CCR3 antagonism) using cells, compds. of this invention showed IC50 values of 0.001 μM to 0.45 μM.

ACCESSION NUMBER: 2002:171853 HCAPLUS
DOCUMENT NUMBER: 136:232201
TITLE: Preparation of cyclic amine derivatives as CCR3 antagonists
INVENTOR(S): Morihira, Koichiro; Inami, Hiroshi; Kubota, Hirokazu; Yokoyama, Kazuhiro; Morokata, Tatsuaki; Takeuchi, Makoto; Takahashi, Toshiya; Kaneko, Masayuki; Imaoka, Takayuki; Torii, Yuichi; Iura, Yosuke
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Toray Industries, Inc.
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018335	A1	20020307	WO 2001-JP7321	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080187	A5	20020313	AU 2001-80187	20010827

PRIORITY APPLN. INFO.: JP 2000-257451 A 20000828
WO 2001-JP7321 W 20010827

OTHER SOURCE(S): MARPAT 136:232201

IT 403617-43-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amine derivs. as CCR3 antagonists)

RN 403617-43-6 HCAPLUS
CN 1,2-Pyrrolidinedicarboxamide, N2-(3-cyano-2-thienyl)-N1-[(3-exo)-8-[(6-fluoro-2-naphthalenyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]-, (2S)- (9CI) (CA INDEX NAME)





IT 403478-55-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic amine derivs. as CCR3 antagonists)

RN 403478-55-7 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(3-cyano-2-thienyl)amino]carbonyl]-, 9H-fluoren-9-ylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L8 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 Dec 2001
GI



AB The title compds. [I; R1, R2 = H, halo, aryl, etc.; or R1 and R2 taken together form (CH2)m(NR4)n(CH2)p (wherein m, p = 1-3; n = 0-1; m + n + p = 3-5; R4 = H, alkyl); R3 = alkyl, alkenyl, aryl, etc.], useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders (no data given), were prepared Thus, amidation of 2-amino-3-carbamoyl-4,5,6,7-tetrahydrobenzo[b]thiophene with phenylacetic acid afforded I [R1R2 = (CH2)4; R3 = CH2Ph].

ACCESSION NUMBER: 2001:935593 HCAPLUS
DOCUMENT NUMBER: 136:69729
TITLE: Preparation of thiophene-3-carboxamides as kinase inhibitors
INVENTOR(S): Fancelli, Daniele; Pevarello, Paolo; Varasi, Mario
PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098290	A2	20011227	WO 2001-EP6763	20010614
WO 2001098290	A3	20020516		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6414013	B1	20020702	US 2000-596550	20000619
CA 2414085	AA	20011227	CA 2001-2414085	20010614
AU 2001085745	A5	20020102	AU 2001-85745	20010614
EP 1294707	A2	20030326	EP 2001-964983	20010614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501146	T2	20040115	JP 2002-504246	20010614
PRIORITY APPLN. INFO.:			US 2000-596550	A 20000619
			WO 2001-EP6763	W 20010614

OTHER SOURCE(S): MARPAT 136:69729
IT **383379-42-8P 383379-77-9P 383380-21-0P 383380-90-3P 383381-04-2P 383381-05-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophene-3-carboxamides as kinase inhibitors)

RN 383379-42-8 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[3-(aminocarbonyl)-4,5,6,7-tetrahydrobenzo[b]thien-2-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 383379-77-9 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-[3-(aminocarbonyl)-5-(1-methylethyl)-2-thienyl]-1-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383380-21-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-acetyl-N-[3-(aminocarbonyl)-5-phenyl-2-thienyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 383380-90-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 1-acetyl-N-[3-(aminocarbonyl)-5-(1-phenylethyl)-2-thienyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 383381-04-2 HCAPLUS
CN 1H-Indole-2-carboxamide, N-[3-(aminocarbonyl)-5-(1-phenylethyl)-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 383381-05-3 HCAPLUS
CN 1H-Indole-3-carboxamide, N-[3-(aminocarbonyl)-5-(1-phenylethyl)-2-thienyl]-1-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L8 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 26 Sep 2000
GI



I II

AB N-linked five-membered heteroaryls were obtained by conversion of 2-carboxy-heteroarenes I (Y = OH, R = H, Me, SiMe3, X = S, Se, O) into N-(2-heteroaryl)-1-methylpyrrole-2-carboxamides II. The procedure is based on a simple thermal rearrangement of thiophene or selenophene carbonyl azides I (Y = N3) in neat 1-methylpyrrole at 90°.

ACCESSION NUMBER: 2000:673727 HCAPLUS
DOCUMENT NUMBER: 134:100944
TITLE: A convenient and efficient conversion of 2-carboxyheteroarenes into and N-(2-thienyl and 2-selenophenyl) 1-methylpyrrole-2-carboxamides
AUTHOR(S): Danielli, Filippo; Zanirato, Paolo
CORPORATE SOURCE: Dip. di Chim. Organica, 'A. Mangini', Univ. di Bologna, Bologna, 40136, Italy
SOURCE: ARKIVOC (online computer file) (2000), 1(1), 67-72
CODEN: AKVCFI
URL: http://www.arkat.org/arkat/journal/Issue1/ARK0000 09/ms9.pdf
PUBLISHER: ARKAT Foundation
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:100944
IT **319447-91-1P 319447-95-5P 319447-97-7P 319447-99-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 319447-91-1 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-2-thienyl- (9CI) (CA INDEX NAME)



RN 319447-95-5 HCAPLUS

Pub 2/21/00

L8 ANSWER 9 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-2-carboxamide, N-2-furanyl-1-methyl- (9CI) (CA INDEX NAME)



RN 319447-97-7 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 319447-99-9 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[5-(trimethylsilyl)-2-thienyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 15 Sep 2000
AB A new aromatic pair, 2-hydroxy-6-methoxybenzamide/1-methylpyrrole at the terminal position of hairpin polyamides has been designed for distinguishing T·A from A·T base pairs and both from G·C/C·G in the minor groove of DNA. Four eight-ring hairpin polyamides with benzamide (Bz), 2-hydroxybenzamide (Hb-1), 2-hydroxy-6-methylbenzamide (Hb-2), and 2-hydroxy-6-methoxybenzamide (Hb-3) at the N-terminal position were synthesized. The equilibrium association consts. (Ka) were determined at four DNA sites which differ at a single common position, 5'-TNTACA-3' (N = T, A, G, C). Quant. DNase I footprint titration expts. reveal that (Hb-3)PyPyPy-(R)H2Ny-ImPyPyPy-β-Dp (4) bound the sequences 5'-TTTACA-3' and 5'-TATACA-3' with high affinity; Ka = 2.6 + 1010 M-1 and Ka = 8.4 + 109 M-1, resp., a 3-fold specificity for T vs. A was found. Importantly, the sequences 5'-TGTACA-3' and 5'-TCTACA-3' are bound with 50 and 200 times lower affinity, revealing an overall specificity of Hb-3/Py of T > A » G > C. These results expand the repertoire of sequences targetable by hairpin polyamides.

ACCESSION NUMBER: 2000:644918 HCAPLUS
DOCUMENT NUMBER: 134:26617
TITLE: Hydroxybenzamide/Pyrrole Pair Distinguishes T·A from A·T Base Pairs in the Minor Groove of DNA
AUTHOR(S): Ellervik, Ulf; Wang, Clay C. C.; Dervan, Peter B.
CORPORATE SOURCE: Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, 91125, USA
SOURCE: Journal of the American Chemical Society (2000), 122(39), 9354-9360
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **312299-02-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(polyamides containing hydroxybenzamide/pyrrole pair distinguish T·A from A·T base pairs in minor groove of DNA)
RN 312299-02-8 HCAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[(3-methoxy-1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 13 Jul 2000
AB Head-to-head linked dimers of heterocyclic amino acids were prepared to investigate their affinity and selectivity in binding to the minor groove of DNA. The selection of targets for synthesis was led by computer based design. Several novel dicarboxylic acid linkers including indoles, phenanthrenes, a fluorenone, and a bisbenzothiophene were included. Anal. of binding to DNA by footprinting showed high affinity for compds. derived from 2,7-dihydrophenanthrenedicarboxylic acid and a predominate selectivity for AT rich regions containing at least four AT pairs but with the ability to span up to two CG base pairs.

ACCESSION NUMBER: 2000:471732 HCAPLUS
DOCUMENT NUMBER: 133:281718
TITLE: The synthesis of some head to head linked DNA minor groove binders
AUTHOR(S): Khalaf, A. I.; Pitt, A. R.; Scobie, M.; Suckling, C. J.; Urwin, J.; Waigh, R. D.; Fishleigh, R. V.; Young, S. C.; Wylie, W. A.
CORPORATE SOURCE: Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, G1 1XL, UK
SOURCE: Tetrahedron (2000), 56(29), 5225-5239
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:281718
IT **299974-91-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of head-to-head linked heterocyclic amino acid dimers with binding affinity to minor groove of DNA)
RN 299974-91-7 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-2-thienyl]-1-methyl-4-nitro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 2000
GI



I II III

AB A process of synthesizing a bicyclo compound (I) is described. Proline (II) is reacted with diphenylphosphinic chloride to activate the carboxylic acid group, and then reacted with methanesulfonyl chloride to produce ester (III) which is then reacted with a group II metal sulfide source in water to produce I.

ACCESSION NUMBER: 2000:307143 HCAPLUS
DOCUMENT NUMBER: 132:321855
TITLE: Process for synthesizing carbapenem side chain intermediates
INVENTOR(S): Brands, Karel M. J.; Williams, John M.; Dolling, Ulf H.; Jobson, Ronald B.; Davies, Antony J.; Cottrell, Ian F.; Cameron, Mark; Ashwood, Michael S.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 13 pp., Division of U.S. Ser. No. 106,297. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6060607	A	20000509	US 1999-334398	19990616
US 6063931	A	20000516	US 1998-106297	19980629
PRIORITY APPLN. INFO.:			US 1998-106297 A3	19980629
			US 1997-52032P P	19970709

OTHER SOURCE(S): CASREACT 132:321855; MARPAT 132:321855
IT **266337-28-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(process for synthesizing carbapenem side chain intermediates)
RN 266337-28-4 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(5-carboxy-2-thienyl)amino]carbonyl]-4-hydroxy-, 1-(1,1-dimethylethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)

L8 ANSWER 12 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Apr 2000
AB A synthetic combinatorial library of 10,000 components mostly containing aromatic
amino acids was screened for inhibition of DNase I cleavage at two ARE sequences. Ten amino acid building blocks were used to generate the library in which the N and C terminal residues were fixed and the four central positions of the peptide ligands were varied. The DNase I footprinting assay led, after deconvolution through sublibrary synthesis, to the identification of CGL-6382 as an ARE-selective minor groove binder containing a N-terminal nicotinic acid motif adjacent to a N-methylimidazole unit and three N-methylpyrrole units coupled to a C-terminal argininamide residue. The optimized ligand CGL-6382 was found to recognize a 5'-GC(A/T)(A/T) motif within the two cloned androgen receptors responsive elements. The discovery of CGL-6382 as an ARE-selective ligand augurs well for the use of the DNase I footprinting methodol. to identify sequence-specific DNA recognition ligands from large mixts. of small mols.
(c) 2000 Academic Press.
ACCESSION NUMBER: 2000:224933 HCAPLUS
DOCUMENT NUMBER: 133:68541
TITLE: An ARE-selective DNA minor groove binder from a combinatorial approach
AUTHOR(S): Hamy, Francois; Albrecht, Genevieve; Florsheimer, Andreas; Bailly, Christian
CORPORATE SOURCE: Department of Oncology, Novartis Pharma Research, Basel, CH-4002, Switz.
SOURCE: Biochemical and Biophysical Research Communications (2000), 270(2), 393-399 CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **278788-95-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(an ARE-selective DNA minor groove binder from a combinatorial approach)
RN 278788-95-7 HCAPLUS
CN 3-Pyridinecarboxamide, N-[2-[[[5-[[[5-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 13 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 01 Dec 1999
AB The synthesis, biol. activity, and DNA-binding properties of a series of four pyrrolo[2,1-c][1,4]benzodiazepine (PBD) hybrids containing polypyrrole side chains are described and structure-activity relationships examined. To investigate sequence selectivity and stability of drug/DNA complexes, DNase I footprinting and arrested polymerase chain reaction (PCR) were performed on human c-myc oncogene, estrogen receptor gene, and human immunodeficiency virus type 1 long terminal repeat (HIV-1 LTR) gene sequences. The antiproliferative activity of the hybrids was tested in vitro on human myeloid leukemia K562 and T-lymphoid Jurkat cell lines and compared to antiproliferative effects of the natural product distamycin A 1, its tetrapyrrole homolog, DC 81, and a PBD ester. The new hybrids exhibit different DNA-binding activity with respect to both distamycin A 1 and the parent PBD. In addition, a direct relationship was found between the number of pyrrole rings present in the hybrids and the stability of drug/DNA complexes. With respect to antiproliferative effects, it was found that the increase in the length of the polypyrrole backbone leads to an increase of in vitro antiproliferative effects, i.e., the hybrid with 4 pyrroles is more active than the other ones both against K562 and Jurkat cell lines.
ACCESSION NUMBER: 1999:758546 HCAPLUS
DOCUMENT NUMBER: 132:137361
TITLE: Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers
AUTHOR(S): Baraldi, Pier Giovanni; Balboni, Gianfranco; Cacciari, Barbara; Guiotto, Andrea; Manfredini, Stefano; Romagnoli, Romeo; Spalluto, Giampiero; Thurston, David E.; Howard, Philip W.; Bianchi, Nicoletta; Rutigliano, Cristina; Mischiati, Carlo; Gambari, Roberto
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche e Dipartimento di Biochimica e Biologia Molecolare, Universita di Ferrara, Ferrara, 44100, Italy
SOURCE: Journal of Medicinal Chemistry (1999), 42(25), 5131-5141
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:137361
IT **256949-69-6P 256949-70-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation, antiproliferative activity, and DNA-binding pyrrolobenzodiazepines containing oligopyrrole carriers)
RN 256949-69-6 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-5-[[[1-methyl-5-[[1-oxo-3-[[(11aS)-2,3,5,11a-tetrahydro-7-methoxy-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]propyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



● HCl

PAGE 1-B



RN 256949-70-9 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-5-[[[1-methyl-5-[[1-oxo-3-[[(11aS)-2,3,5,11a-tetrahydro-7-methoxy-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]propyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



● HCl

PAGE 1-B



IT **256949-62-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(preparation, antiproliferative activity, and DNA-binding pyrrolobenzodiazepines containing oligopyrrole carriers)
RN 256949-62-9 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-5-[[(5-amino-1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



●2 HCl

PAGE 1-B



IT **256949-61-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation, antiproliferative activity, and DNA-binding pyrrolobenzodiazepines containing oligopyrrole carriers)
RN 256949-61-8 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-5-[[(5-amino-1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **256949-65-2P 256949-66-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, antiproliferative activity, and DNA-binding pyrrolobenzodiazepines containing oligopyrrole carriers)

L8 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 256949-65-2 HCAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8-[3-[[5-[[[5-[[[3-amino-3-iminopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]-3-oxopropoxy]-2,3,11,11a-tetrahydro-11-hydroxy-7-methoxy-5-oxo-, 2,2,2-trichloroethyl ester, monohydrochloride, (11S,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B



RN 256949-66-3 HCAPLUS
CN 1H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylic acid, 8-[3-[[5-[[[5-[[[5-[[[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino)-3-oxopropoxy]-2,3,11,11a-tetrahydro-11-hydroxy-7-methoxy-5-oxo-, 2,2,2-trichloroethyl ester, monohydrochloride, (11S,11aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 14 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



● HCl

PAGE 1-B



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 26 Aug 1998
GI



I



II

AB The title compds., e.g. I [R1 represents optionally substituted aralkyl, etc.; Z represents optionally alkylated nitrogen, etc.; X1 represents CH2NHCO, etc.; X2 represents phenylene, etc.; X3 represents a single bond, etc.; Y2 represents optionally substituted aryl, etc.; and B represents oxygen, etc.], are prepared. In an in vitro test for cPLA2 inhibition, the title compound II showed IC50 of 0.17 μM.

ACCESSION NUMBER: 1998:543071 HCAPLUS
DOCUMENT NUMBER: 129:161558
TITLE: Preparation and formulation of thiazolidinedione derivatives as phospholipase A2 inhibitors
INVENTOR(S): Seno, Kaoru; Ohtani, Mitsuaki; Watanabe, Fumihiko
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833797	A1	19980806	WO 1998-JP307	19980127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 577875	B	20040301	TW 1998-87101064	19980126
CA 2277947	AA	19980806	CA 1998-2277947	19980127
CA 2277947	C	20040921		

L8 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AU 9855775	A1	19980825	AU 1998-55775	19980127
AU 719210	B2	20000504		
BR 9807132	A	20000125	BR 1998-7132	19980127
EP 976748	A1	20000202	EP 1998-900741	19980127
EP 976748	B1	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
TR 9901847	T2	20000621	TR 1999-9901847	19980127
RU 2198174	C2	20030210	RU 1999-119481	19980127
AT 255579	E	20031215	AT 1998-900741	19980127
PT 976748	T	20040331	PT 1998-900741	19980127
ES 2210710	T3	20040701	ES 1998-900741	19980127
US 6147100	A	20001114	US 1999-355008	19990722
NO 9903706	A	19990930	NO 1999-3706	19990729
NO 313881	B1	20021216		
MX 9907061	A	20000228	MX 1999-7061	19990729
PRIORITY APPLN. INFO.:			JP 1997-17962	A 19970131
			WO 1998-JP307	W 19980127

OTHER SOURCE(S): MARPAT 129:161558
IT **211297-31-3P 211297-34-6P 211298-04-3P 211298-06-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinedione derivs. as phospholipase A2 inhibitors)
RN 211297-31-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 4-([1,1'-biphenyl]-2-ylmethoxy)-1-[2-(4-fluorobenzoyl)benzoyl]-N-[5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-2-thienyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 211297-34-6 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 4-([1,1'-biphenyl]-2-ylmethoxy)-N-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2-thienyl]-1-[2-(4-methylbenzoyl)benzoyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

L8 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry unknown.



RN 211298-04-3 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[([1,1'-biphenyl]-2-ylmethyl)thio]-N-[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2-thienyl]-1-[2-(4-fluorobenzoyl)benzoyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L8 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1-Pyrrolidinecarboxylic acid, 4-([1,1'-biphenyl]-2-ylmethoxy)-2-[[[5-[(2,4-dioxo-5-thiazolidinylidene)methyl]-2-thienyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 211298-06-5 HCAPLUS
CN 2-Pyrrolidinecarboxamide, 4-[([1,1'-biphenyl]-2-ylmethyl)thio]-1-[2-(4-fluorobenzoyl)benzoyl]-N-[5-[(4-oxo-2-thioxo-5-thiazolidinylidene)methyl]-2-thienyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 211298-68-9P 211298-69-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolidinedione derivs. as phospholipase A2 inhibitors)
RN 211298-68-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-([1,1'-biphenyl]-2-ylmethoxy)-2-[[(5-formyl-2-thienyl)amino]carbonyl]-, 1,1-dimethylethyl ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 211298-69-0 HCAPLUS

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Aug 1997
AB A new upper limit of binding site size is defined for the hairpin polyamide-DNA motif. Ten-ring hairpin polyamides containing pyrrole (Py) and imidazole (Im) amino acids were designed for recognition of seven base pair (bp) sequences in the minor groove of DNA. The DNA binding properties of two polyamides, ImPyPyPyPy-γ-ImPyPyPyPy-β-Dp, and ImImPyPyPy-γ-ImPyPyPyPy-β-Dp were analyzed by footprinting and affinity cleavage on a DNA fragment containing the resp. match sites 5'-TGTAACA-3' and 5'-TGGAACA-3'. Quant. footprint titrns. demonstrate that ImPyPyPyPy-γ-ImPyPyPyPy-β-Dp binds the 7-bp match sequence 5'-TGTAACA-3' with an equilibrium association constant (Ka) of Ka = 1.2 + 1010 M-1 and 18-fold specificity vs. the single base pair mismatch sequence 5'-TGGAACA-3'. ImImPyPyPy-γ-ImPyPyPyPy-β-Dp differs from ImPyPyPyPy-γ-ImPyPyPyPy-β-Dp by a single amino acid substitution and binds its match 5'-TGGAACA-3' site with Ka = 3.6 + 109 M-1 and 300-fold specificity vs. its corresponding single base pair mismatch sequence 5'-TGTAACA-3'. Ten-ring hairpin polyamides have binding affinities similar to those of eight-ring hairpin polyamides. These results indicate that the affinity of hairpin binding ceases to increase as the length of the polyamide subunits increases beyond four rings, analogous to the behavior of unlinked subunits. Therefore, recognition of seven base pairs by a ten-ring hairpin polyamide most likely represents an upper limit to the effective targetable site size of the hairpin polyamide-DNA motif.
ACCESSION NUMBER: 1997:528757 HCAPLUS
DOCUMENT NUMBER: 127:216506
TITLE: Recognition of Seven Base Pair Sequences in the Minor Groove of DNA by Ten-Ring Pyrrole-Imidazole Polyamide Hairpins
AUTHOR(S): Turner, James M.; Baird, Eldon E.; Dervan, Peter B.
CORPORATE SOURCE: Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA, 91125, USA
SOURCE: Journal of the American Chemical Society (1997), 119(33), 7636-7644
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 194857-41-5P 194857-42-6P
RL: BPR (Biological process); BSU (Biological study, unclassified); CAT (Catalyst use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of and recognition of seven base pair sequences in the minor groove of DNA by ten-ring pyrrole-imidazole polyamide hairpins)
RN 194857-41-5 HCAPLUS
CN Iron, [2,3,4,5-tetradehydro-1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1-oxobutyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]prolyl-N-[15-(carboxy-κO)-11,14-bis[(carboxy-κO)methyl]-4-methyl-9-oxo-4,8,11,14-tetraazapentadec-1-yl-κN11,κN14]-β-alaninamidato(3-)]-(9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-C



PAGE 2-A



L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-B



PAGE 2-C



RN 194857-42-6 HCAPLUS
CN Iron, {2,3,4,5-tetradehydro-1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1-oxobutyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]prolyl-N-[15-(carboxy-κO)-11,14-bis[(carboxy-κO)methyl]-4-methyl-9-oxo-4,8,11,14-tetraazapentadec-1-yl-κN11,κN14]-β-alaninamidato(3-)]-(9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-C



PAGE 2-A



L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-B



PAGE 2-C



IT 194857-40-4P 194857-49-3P 194857-50-6P
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of and recognition of seven base pair sequences in the minor groove of DNA by ten-ring pyrrole-imidazole polyamide hairpins)
RN 194857-40-4 HCAPLUS
CN 1H-Imidazole-2-carboxamide, 1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]-N-[1-methyl-5-[[[1-methyl-5-[[[1-methyl-5-[[[4-[[1-methyl-2-[[[1-methyl-5-[[[1-methyl-5-[[[1-methyl-5-[[[3-[[3-(methylamino)propyl]amino]-3-oxopropyl]amino]carbonyl]-1H-pyrrol-2-yl]amino]carbonyl]-1H-pyrrol-2-yl]amino]carbonyl]-1H-pyrrol-2-yl]amino]carbonyl]-1H-pyrrol-2-yl]amino]carbonyl]-1H-imidazol-4-yl]amino]-4-oxobutyl]amino]carbonyl]-1H-pyrrol-3-yl]amino]carbonyl]-1H-pyrrol-3-yl]amino]carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 194857-49-3 HCAPLUS
CN β-Alaninamide, 2,3,4,5-tetradehydro-1-methyl-4-{[[1-methyl-4-[[[1-methyl-4-{[[1-methyl-4-{[[1-methyl-4-[[4-[[[1-methyl-4-{[[1-methyl-4-[[[1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1-oxobutyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]prolyl-N-{15-carboxy-11,14-bis(carboxymethyl)-4-methyl-9-oxo-4,8,11,14-tetraazapentadec-1-yl}-(9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 194857-50-6 HCAPLUS
CN β-Alaninamide, 2,3,4,5-tetradehydro-1-methyl-4-{[{1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1-oxobutyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]prolyl-N-{15-carboxy-11,14-bis(carboxymethyl)-4-methyl-9-oxo-4,8,11,14-tetraazapentadec-1-yl}-(9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C



L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



IT 194857-46-0DP, conjugates with Pam resin 194857-47-1P
194857-48-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of and recognition of seven base pair sequences in the minor groove of DNA by ten-ring pyrrole-imidazole polyamide hairpins)

RN 194857-46-0 HCAPLUS

CN β-Alanine, 2,3,4,5-tetradehydro-1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-1H-imidazol-2-yl]carbonyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1-oxobutyl]amino]-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]prolyl-, [4-(carboxymethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C



L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 194857-47-1 HCAPLUS

CN 1H-Imidazole-2-carboxamide, N-[5-[[[5-[[[5-[[[3-[[3-[(3-aminopropyl)amino]propyl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-4-[[4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-4-[[[1-methyl-1H-imidazol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1-oxobutyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C

PAGE 2-A



RN 194857-48-2 HCAPLUS

CN 1H-Imidazole-2-carboxamide, N-[5-[[[5-[[[5-[[[4-[[2-[[[5-[[[5-[[[5-[[[3-[[3-[(3-aminopropyl)amino]propyl]amino]-3-oxopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]-4-oxobutyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-4-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 1-C

L8 ANSWER 16 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 27 Apr 1996
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is directed to novel cyclopropylpyrroloindole-oligopeptide compds. which are useful as anticancer agents. The novel cyclopropylpyrroloindole-oligopeptide compds. have the following general structure: I wherein, Het1 and Het2 are individually selected from the group consisting of pyrrole, imidazole, N-alkylimidazole, N-alkoxymethylimidazole, thiophene, thiophene, furan, thiazole, oxazole, N-alkylpyrrole, N-alkoxymethylpyrrole and pyrazole, R is selected from the group consisting of a valence bond; a divalent C1-C6 alkyl; a divalent C2-C6 alkenyl; a divalent C2-C6 alkynyl; a divalent cycloalkane of formula CpH2p-2 wherein p is 3 to 7; and an ortho, meta or para linked aromatic group, A is selected from the group consisting of a C1-C6 alkyl group; an amidine or derivative thereof; a guanidine; a secondary, tertiary or quaternary ammonium salt; and a sulfonium salt, n is 0 to 3, and m is 0 to 3, wherein when n=0, m is 1-3. Thus, e.g., deprotection of 5-benzyloxy-3-tert-butyloxycarbonyl-1-chloromethyl-8-methyl-1,2-dihydro-3H-pyrrolo[3,2-e]indole (II) followed by coupling with 4-(4-butyramido-N-methyl-2-pyrrolecarboxyamido)-N-methyl-2-pyrroleacrylic acid and ring closure afforded (E)-1,2,8,8a-tetrahydro-7-methyl-2-[4-(4-butyramido-N-methyl-2-pyrrolecarboxyamido)-N-methyl-2-pyrroleacryloyl]cyclopropa[c]pyrroloindole-4-(5H)-one [(E)-III] which exhibited cytotoxicity of TD50 = 9.50 + 10-10 μg/mL for KB human nasopharyngeal tumor cells (TD50 = 1 + 10-6 μg/mL for CC-1065). A detailed anal. of the frequency of occurrence of bases flanking the prominent DNA alkylation sites for III is given and compared with CC-1065, providing evidence of the main cellular event that gives rise to the expression of anticancer properties of the new drugs and how they differ in detail from CC-1065.

ACCESSION NUMBER: 1996:248963 HCAPLUS
DOCUMENT NUMBER: 125:11480
TITLE: Cyclopropapyrroloindole-oligopeptide anticancer agents
INVENTOR(S): Lown, J. William; Wang, Yuqiang; Luo, Weide
PATENT ASSIGNEE(S): Synphar Laboratories, Inc., Can.
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5502068	A	19960326	US 1995-381355	19950131
CA 2210093	AA	19960808	CA 1996-2210093	19960131
WO 9623497	A1	19960808	WO 1996-US727	19960131
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
AU 9649643	A1	19960821	AU 1996-49643	19960131
AU 698001	B2	19981022		
EP 800390	A1	19971015	EP 1996-906176	19960131
EP 800390	B1	20021204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				

L8 ANSWER 17 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

JP 11500427	T2	19990112	JP 1996-523576	19960131
AT 228837	E	20021215	AT 1996-906176	19960131
PRIORITY APPLN. INFO.:			US 1995-381355	A 19950131
			WO 1996-US727	W 19960131

OTHER SOURCE(S): MARPAT 125:11480
IT 177177-56-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclopropapyrroloindole-oligopeptide anticancer agents)
RN 177177-56-9 HCAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 4-[[[4-[[[4-[[3-(dimethylamino)-1-oxopropyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 23 Dec 1995
GI



AB Novel aminoalkyl substituted indolocarbazoles I (R = Q1 (n = 1, 2, 3), HN(CH2)3NMe2, etc.) were prepared from staurosporine aglycon and characterized with respect to inhibition of protein kinases C and A. In both series, potent and selective PKC inhibitors could be identified. Structure activity relationships are discussed.

ACCESSION NUMBER: 1995:1002143 HCAPLUS
DOCUMENT NUMBER: 124:175641
TITLE: Novel substituted indolocarbazoles as potent and selective inhibitors of protein kinase C
AUTHOR(S): Xie, Guojian; Nagata, Hiroyuki; Tamaoki, Tatsuya; Lown, J. William
CORPORATE SOURCE: Dep. Chem., Univ. Alberta, Alberta, T6G 2G2, Can.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(23), 2841-4
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **173917-98-1P 173917-99-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and protein kinase inhibitory activity of indolocarbazoles)

RN 173917-98-1 HCAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-methyl-5-[[[1-methyl-5-[[1-oxo-3-(5,6,7,13-tetrahydro-7-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 173917-99-2 HCAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-methyl-5-[[[1-methyl-5-[[[1-methyl-5-[[1-oxo-3-(5,6,7,13-tetrahydro-7-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



IT **173917-95-8 173917-96-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and protein kinase inhibitory activity of indolocarbazoles)

RN 173917-95-8 HCAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[(5-amino-1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 18 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 173917-96-9 HCAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[[5-[[(5-amino-1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 14 Dec 1995
GI



AB Title compds. [I; R1 = H, halo, alkyl, alkoxy, etc.; R2 = (acyl)alkyl, acyl, CH:CHCO2H, etc.; R3 = H, alkyl, CH2Ph; R4 = SH, SnR, SeH, SenR, etc.; R = H, alkyl, (hetero)aryl, I in which R4 = bond, etc.; R4R5 = S, Se; R5R6 = bond; R6 = H; n = 1-3] were prepared 2Hus, 1-methyl-2-indolinone was treated with P2S5 and the product condensed with PhNCO to give, after oxidation, title compound II which had IC50 of 3-4μM against growth factor mediated mitogenesis in vitro.

ACCESSION NUMBER: 1995:982654 HCAPLUS
DOCUMENT NUMBER: 124:175826
TITLE: Preparation of 2-indolyldisulfides and analogs as protein tyrosine kinase inhibitors and antitumor agents
INVENTOR(S): Dobrusin, Ellen M.; Showalter, Howard D. H.; Denny, William A.; Palmer, Brian D.; Rewcastle, Gordon W.; Tercel, Moana; Thompson, Andrew M.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 53 pp. Cont.-in-part of U.S. Ser. No. 926, 015, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5464861	A	19951107	US 1993-94792	19930809
HU 71553	A2	19951228	HU 1995-341	19930802
CZ 283965	B6	19980715	CZ 1995-288	19930802
NZ 255194	A	20000128	NZ 1993-255194	19930802
US 5556874	A	19960917	US 1995-438616	19950510
PRIORITY APPLN. INFO.:			US 1992-926015	B2 19920806
			US 1993-94792	A3 19930809

OTHER SOURCE(S): MARPAT 124:175826
IT **156136-37-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-indolyldisulfides and analogs as protein tyrosine kinase inhibitors and antitumor agents)
RN 156136-37-7 HCAPLUS
CN 1H-Indole-3-carboxamide, 2,2'-dithiobis[1-methyl-N-2-thienyl- (9CI) (CA INDEX NAME)

L8 ANSWER 19 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L8 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 10 Jan 1995
AB A series of 3-substituted 2,2'-dithiobis(1H-indoles) were synthesized and evaluated for their ability to inhibit the tyrosine kinase activity of both the epidermal growth factor receptor (EGFR) and the nonreceptor pp60v-src tyrosine kinase, to extend the available structure-activity relationships for this series. The majority of the compds. were prepared either by reaction of 2-chloro-1-methylindole-3-carbonyl chloride with amines, followed by thiomethylation, demethylation, and oxidative dimerization, or by reaction of isocyanates with the anion of 1-methyl-2-indolinethione followed by dimerization. Overall, inhibitory activity is retained by analogs having a wide variety of side chains. A series of 3-carboxamide analogs had moderate to good activity against isolated EGFR (IC50s 1-20 μM), with monoalkyl substitution of the carboxamide being optimal. Polar side chains were generally less effective than lipophilic ones, with benzyl being particularly effective. However, N,N-disubstitution was the most effective pattern for inhibition of pp60v-src. A variety of substituted N-phenylcarboxamides had lower activity against EGFR than the parent derivative, and a N-thienylcarboxamide also had low activity. A series of 3-ketones, including Me, Ph, and furyl derivs., showed moderate activity against the pp60v-src kinase, but were less effective against EGFR. The mechanism of inhibition of both kinases by these drugs was shown to be noncompetitive with respect to both ATP and peptide substrate. Selected compds. inhibited the growth of Swiss 3T3 cells with IC50s in the low micromolar range and inhibited bFGF-mediated intracellular tyrosine phosphorylation in the same cell line. Thiol inhibits the effects of the compds., suggesting that one possible mechanism of inhibition is thiol-disulfide exchange with thiol-containing residues in the catalytic sites. Crystal structures of two representative compds. show a folded, V-shaped structure, with the disulfide bridge exposed, consistent with this hypothesis.

ACCESSION NUMBER: 1995:283548 HCAPLUS
DOCUMENT NUMBER: 123:248
TITLE: Tyrosine Kinase Inhibitors. 4. Structure-Activity Relationships among N- and 3-Substituted 2,2'-Dithiobis(1H-indoles) for in vitro Inhibition of Receptor and Nonreceptor Protein Tyrosine Kinases
AUTHOR(S): Palmer, Brian D.; Rewcastle, Gordon W.; Thompson, Andrew M.; Boyd, Maruta; Showalter, H. D. Hollis; Sercel, Anthony D.; Fry, David W.; Kraker, Alan J.; Denny, William A.
CORPORATE SOURCE: School of Medicine, University of Auckland, Auckland, 92019, N. Z.
SOURCE: Journal of Medicinal Chemistry (1995), 38(1), 58-67
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **156136-37-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(structure-activity relationships among dithiobisindoles for inhibition of receptor and nonreceptor protein tyrosine kinases)
RN 156136-37-7 HCAPLUS
CN 1H-Indole-3-carboxamide, 2,2'-dithiobis[1-methyl-N-2-thienyl- (9CI) (CA INDEX NAME)

L8 ANSWER 20 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L8 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 17 Nov 1994
AB In the present study, the authors have investigated the effect of unprecedented chemical modifications introduced in the distamycin mol., with the aim of assessing their ability to interfere with sequence-specific DNA-protein interactions in vitro. By using an electrophoretic mobility shift assay, the authors have been able to identify novel distamycin analogs with improved displacing abilities on the binding of octamer nuclear factors to their target DNA sequence. While variations in the number of pyrrole rings and/or reversion of an internal amide bond result in distamycin-like compds. with identical or very similar properties, the reversion of the formamido into a carboxyamido group or its replacement with the charged formimidoyl moiety significantly improves the ability of the resulting novel distamycin derivs. to compete with OCT-1 (octamer 1 nuclear factor) for its target DNA sequence. Tissue-specific octamer-dependent in vitro transcription is similarly affected by these chemical modifications, suggesting that the ability of distamycins to bind octamer sequences has a direct influence on the functional state of octamer-containing promoters. These data represent an initial, successful attempt to rationalize the design of DNA binding drugs, using distamycins as a model.
ACCESSION NUMBER: 1995:199500 HCAPLUS
DOCUMENT NUMBER: 122:45671
TITLE: Distamycin analogs with improved sequence-specific DNA binding activities
AUTHOR(S): Ciucci, Alessandra; Feriotto, Giordana; Mischiati, Carlo; Gambari, Roberto; Animati, Fabio; Lombardi, Paolo; Natali, Pier Giorgio; Arcamone, Federico; Giacomini, Patrizio
CORPORATE SOURCE: Menarini Ricerche Sud, Italy
SOURCE: Biochemical Pharmacology (1994), 48(8), 1583-91
CODEN: BCPCA6; ISSN: 0006-2952
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 159565-63-6, MEN 10398 159565-64-7, MEN 10557
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(distamycin analogs with improved sequence-specific DNA binding activities)
RN 159565-63-6 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 21 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 159565-64-7 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N4-[4-[[[4-(aminocarbonyl)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-N2-(3-amino-3-iminopropyl)-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 10 Dec 1994
GI



I

AB Title compds. I (A = (substituted) Ph or thienyl; R1 = MeCH(OH), MeCHF, HOCH2; R2 = H, C1-4 alkyl; R3, R4 = H, halo, NC, C1-4 alkyl, O2N, HO, HO2C, C1-4 alkoxy, F3C, etc.; X = c1-6 alkanediyl interrupted by O, S(O)x wherein x = 0-2, R5NCO wherein R5 = H, C1-4 alkyl) or a salt or in vivo hydrolysable ester , are prepared To allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-allyloxycarbonyl-2-(3(E-allyloxycarbonyl-1-ethenyl)phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (preparation given) and Maldrum's acid in DMF and THF was added (Ph3P)4Pd followed by Na 2-ethylhexanoate to give the title compound (1R,5S,6S,8R,2'S,4'S)-2-(2-(3(E-2-carboxy-1-ethenyl)phenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid, di-Na salt (II). In vitro against S. aureus the min. inhibitory concentration of II was 0.13 μg/mL ws. 2.0 μg/mL of ceftriaxone. Pharmaceutical formulations comprising I are given.
ACCESSION NUMBER: 1994:680467 HCAPLUS
DOCUMENT NUMBER: 121:280467
TITLE: Preparation of antibiotic carbapenem compounds
INVENTOR(S): Betts, Michael John; Davies, Gareth Morse; Jung, Frederic Henri
PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 590885	A1	19940406	EP 1993-307551	19930923
EP 590885	B1	20000315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2106141	AA	19940329	CA 1993-2106141	19930914
US 5527791	A	19960618	US 1993-123998	19930921
AT 190615	E	20000415	AT 1993-307551	19930923
ES 2144446	T3	20000616	ES 1993-307551	19930923
JP 06211860	A2	19940802	JP 1993-241519	19930928
PRIORITY APPLN. INFO.:			EP 1992-402648 A	19920928
OTHER SOURCE(S):	MARPAT 121:280467			

IT **154308-86-8P 154308-87-9P 158743-30-7P 158743-31-8P 158743-32-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of carbapenem antibiotics)
RN 154308-86-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

L8 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 154308-87-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-carboxy-2-thienyl]amino]carbonyl]-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158743-30-7 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-[[(carboxymethyl)amino]carbonyl]-2-thienyl]amino]carbonyl]-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158743-31-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[[(carboxymethyl)amino]carbonyl]-2-thienyl]amino]carbonyl]-4-mercapto-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 22 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 158743-32-9 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[[5-[[(carboxymethyl)amino]carbonyl]-2-thienyl]amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, 2-[(4-nitrophenyl)methyl] ester, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L8 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 03 Sep 1994
GI



I

AB Title compds. I (R1 = MeCHMe, MeCHF, HOCH2; R2 = H, C1-4 alkyl; Z = HO2C, HO3S, tetrazol-5-yl, C1-4alkyl-SO2NHCO; A = (substituted)Ph or thienyl) a pharmaceutically acceptable salt or in vivo hydrolyzable ester thereof, are prepared 2-Thiophenecarboxylic acid was nitated to give the 4-nitro derivative, reduced ti the 4-amino derivative converted to the (2S,4S)-1-(4-nitrobenzylcarbonyl)-2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthioacetate which in in 4 steps was converted to (5R,6S,8R,2'S,4'S)-I (R1 = MeCHOH, R2 = H, A = 4-thienyl, Z = 2-HO2C) which had a min. inhibitory concentration of 0.5 mg/mL against Enterobacter cloacae 108 vs 32 mg/L of ceftriaxone. Pharmaceutical formulations comprising I are given.

ACCESSION NUMBER: 1994:508368 HCAPLUS
DOCUMENT NUMBER: 121:108368
TITLE: Preparation of antibiotic pyrrolidinylthiopenem derivatives
INVENTOR(S): Siret, Patrice Jean
PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.
SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 592167	A1	19940413	EP 1993-307843	19931001
EP 592167	B1	19991222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2106330	AA	19940408	CA 1993-2106330	19930916
AT 187968	E	20000115	AT 1993-307843	19931001
ES 2140445	T3	20000301	ES 1993-307843	19931001
JP 06211871	A2	19940802	JP 1993-250437	19931006
US 5538962	A	19960723	US 1993-132256	19931006
PRIORITY APPLN. INFO.:			EP 1992-402733 A	19921007

OTHER SOURCE(S): MARPAT 121:108368
IT **154308-86-8P 155481-44-0P 156631-45-7P 156631-46-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antibiotics)
RN 154308-86-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

L8 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 155481-44-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-mercapto-2-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156631-45-7 HCAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, 2-propenyl ester, [5R-[3(3S*,5S*),5α,6α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 23 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 156631-46-8 HCAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, 2-propenyl ester, [5R-[3(3S*,5S*),5α,6α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 03 Sep 1994
AB A simple 10-membered monocyclic 3-ene-1,5-diyne has been prepared tethered to a derivative of netropsin. It is proposed that the attachment to this reactive diyne-ene to a mol. which assocs. with B-DNA in the minor groove can enhance the potency of the diyne-ene as a DNA cleavage agent. The nature of the tether appears to be very important in the magnitude of this enhancement, based on two examples reported here. With a two-carbon tether, there is a small increase in DNA cleavage compared with the parent diyne-ene. However, a four-carbon tether, based on a crotonate linkage, shows almost a 2000-fold enhancement of the parent diyne-ene. DNA binding studies using CD measurements and ethidium bromide displacement show that the relative binding constant of the diyne-ene and the two versions tethered to netropsin parallel the DNA cleavage effectiveness.
ACCESSION NUMBER: 1994:499071 HCAPLUS
DOCUMENT NUMBER: 121:99071
TITLE: The Effect on DNA Cleavage Potency of Tethering a Simple Cyclic Enediyne to a Netropsin Analog
AUTHOR(S): Semmelhack, M. F.; Gallagher, J. J.; Ding, W.-d.; Krishnamurthy, G.; Babine, R.; Ellestad, G. A.
CORPORATE SOURCE: Department of Chemistry, Princeton University, Princeton, NJ, 08544, USA
SOURCE: Journal of Organic Chemistry (1994), 59(16), 4357-9
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 156055-65-1
RL: BIOL (Biological study)
(DNA-cleaving activity of and reaction with monocyclic enediynes of, structure in relation to)
RN 156055-65-1 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-amino-N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl- (9CI) (CA INDEX NAME)



IT 156055-66-2P 156055-69-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and DNA-cleaving activity of, structure in relation to)
RN 156055-66-2 HCAPLUS
CN Acetic acid, (4-cyclododecene-2,6-diyn-1-yloxy)-, compd. with 4-amino-N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-1H-pyrrole-2-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 156055-65-1
CMF C15 H21 N7 O2

L8 ANSWER 24 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 156055-64-0
CMF C14 H16 O3



RN 156055-69-5 HCAPLUS
CN 2-Butenoic acid, 4-(4-cyclododecene-2,6-diyn-1-yloxy)-, compd. with 4-[(3-amino-3-imino-1-oxopropyl)amino]-N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-1H-pyrrole-2-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 156055-68-4
CMF C18 H25 N9 O3



CM 2

CRN 156055-67-3
CMF C16 H18 O3



L8 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 20 Aug 1994
GI



AB Title compds. [I; R1 = H, halo, OH, alkyl, alkoxy, CO2H, etc.; 1 or 2 CR1 = N; R2 = (acyl)alkyl, CH:CHCO2H, alkylcarbabamoyl, acyl, etc.; R3 = H, alkyl, CH2Ph; R4 = ZH, ZnX, ZnQ; R5 = H and R4R6 = S or Se; R5R6 = bond; Q = I in which R4 = Zn and R5R6 = bond; X = H, alkyl, CH2Ph, (hetero)aryl; Z = S, Se; n = 0-3] were prepared Thus, 1-methyl-2-indolinone was treated with P2S5 and the product treated with NaH and PhNCO to give indolinethionecarboxamide II which had IC50 of 2μM against epidermal growth factor mediated mitogenisis.
ACCESSION NUMBER: 1994:483050 HCAPLUS
DOCUMENT NUMBER: 121:83050
TITLE: Preparation of 2-indolinethiones and related disulfides and seleno-analogs as protein tyrosine kinase inhibitors and antitumor agents
INVENTOR(S): Dobrusin, Ellen Myra; Showalter, Howard Daniel Hollis; Denny, William Alexander; Palmer, Brian Desmond; Rewcastle, Gordon William; Tercel, Moana; Thompson, Andrew Mark
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9403427	A1	19940217	WO 1993-US7272	19930802
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 654024	A1	19950524	EP 1993-918594	19930802
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 71553	A2	19951228	HU 1995-341	19930802
JP 08503450	T2	19960416	JP 1993-519671	19930802
AU 672224	B2	19960926	AU 1993-47994	19930802
AU 9347994	A1	19940303		
CZ 283965	B6	19980715	CZ 1995-288	19930802
NZ 255194	A	20000128	NZ 1993-255194	19930802
RU 2155187	C2	20000827	RU 1995-108332	19930802
SK 283413	B6	20030701	SK 1995-135	19930802
PRIORITY APPLN. INFO.:			US 1992-926015 A	19920806
			WO 1993-US7272 W	19930802

OTHER SOURCE(S): MARPAT 121:83050
IT 156136-36-6P 156136-37-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as protein tyrosine kinase inhibitor)
RN 156136-36-6 HCAPLUS
CN 1H-Indole-3-carboxamide, 2,2'-dithiobis[N-2-furanyl-1-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 25 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 156136-37-7 HCAPLUS
CN 1H-Indole-3-carboxamide, 2,2'-dithiobis[1-methyl-N-2-thienyl- (9CI) (CA INDEX NAME)



L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 09 Jul 1994
GI



I

II

AB Title compds. I [R = (un)substituted carboxythienyl; R1 = CHMeOH, CHMeF, CH2OH; R2, R3 = H, alkyl] were prepared Thus, the carbapenem II was obtained from the diphenylphosphoryloxycarbapenem and the thiol, prepared from 2-thiophenecarboxylic acid and the protected mercaptopyrrolidinecarboxylic acid in 4 steps. II had min. inhibitory concns. against Staphylococcus aureus Oxford 0.125 and Escherichia coli DC0 0.008 μg/mL.

ACCESSION NUMBER: 1994:409029 HCAPLUS
DOCUMENT NUMBER: 121:9029
TITLE: Carbapenem derivatives as antibiotics and intermediates thereof
INVENTOR(S): Jung, Frederic Henri
PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S. A.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319070	A1	19930930	WO 1993-GB603	19930324
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KZ, LK, LU, MG, NL, NO, PL, RO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
ZA 9301611	A	19930927	ZA 1993-1611	19930305
IL 105135	A1	20000131	IL 1993-105135	19930323
AU 9337636	A1	19931021	AU 1993-37636	19930324
AU 662972	B2	19950921		
EP 586663	A1	19940316	EP 1993-906740	19930324
EP 586663	B1	19990929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 65713	A2	19940728	HU 1993-3304	19930324

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

JP 06508372	T2	19940922	JP 1993-516398		19930324
JP 3313366	B2	20020812			
AT 185140	E	19991015	AT 1993-906740		19930324
ES 2136124	T3	19991116	ES 1993-906740		19930324
CA 2108356	C	20040120	CA 1993-2108356		19930324
CN 1077957	A	19931103	CN 1993-102800		19930326
CN 1036713	B	19971217			
NO 9304264	A	19931125	NO 1993-4264		19931125
FI 104075	B1	19991115	FI 1993-5245		19931125
US 5519015	A	19960521	US 1993-142459		19931126
PRIORITY APPLN. INFO.:			EP 1992-400836	A	19920326
			EP 1992-402763	A	19921009
			WO 1993-GB603	A	19930324

OTHER SOURCE(S): MARPAT 121:9029
IT **154308-86-8P 155481-34-8P 155481-36-0P**
155481-37-1P 155481-38-2P 155481-40-6P
155481-41-7P 155481-42-8P 155481-43-9P
155481-44-0P 155481-45-1P 155481-51-9P
155481-52-0P 155481-53-1P 155549-48-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of carboxythienylcarbamoylpyrrolidinylthiocarbapenemcarboxylates)
RN 154308-86-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155481-34-8 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[[[4-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, 2-propenyl ester, (4R-[3(3S*,5S*),4α,5β,6β(R*)]]-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 155481-33-7
CMF C34 H36 N4 O11 S2

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 7087-68-5
CMF C8 H19 N



RN 155481-36-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[4-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155481-37-1 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(3-carboxy-4,5,6,7-tetrahydrobenzo[b]thien-2-yl]amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, 2-(2-propenyl) ester, (4R-[3(3S*,5S*),4α,5β,6.beta.(R*)]]- (9CI) (CA INDEX NAME)

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 155481-38-2 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[3-carboxy-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)amino]carbonyl]-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155481-40-6 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(3-carboxy-4-methyl-2-thienyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, 2-(2-propenyl) ester, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 155481-39-3
CMF C32 H34 N4 O11 S2

Absolute stereochemistry.

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 7087-68-5
CMF C8 H19 N



RN 155481-41-7 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[3-(ethoxycarbonyl)-4-methyl-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155481-42-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[(3-carboxy-4-methyl-2-thienyl)amino]carbonyl]-4-mercapto-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155481-43-9 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 155481-44-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-mercapto-2-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155481-45-1 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(5-carboxy-3-hydroxy-2-thienyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, [4R-[3(4S*,5S*),4α,5β,6β(R*)]]- (9CI) (CA INDEX NAME)



● Na

RN 155481-51-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[3-(1,1-dimethylethoxy)-5-[(1,1-dimethylethoxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155481-52-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-carboxy-3-hydroxy-2-thienyl]amino]carbonyl]-4-mercapto-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 155481-53-1 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(5-carboxy-3-hydroxy-2-thienyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, 2-(2-propenyl) ester, [4R-[3(3S*,5S*),4α,5α,6β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 26 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155549-48-7 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(5-carboxy-3-hydroxy-2-thienyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4α,5α,6β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 28 May 1994
GI



AB Title compds. [I; R1 = 1-hydroxyethyl, 1-fluoroethyl, hydroxymethyl; R2, R3 = H, alkyl; R4 = Q1-Q3; Z = carboxy, sulfonic acid, sulfinic acid, phenylsulfonylcarbamoyl, alkoxycarbamoyl, alkanesulfonamido, cyanocarbamoyl, tetrazol-5-yl, 3-hydroxyisoxazol-4-yl, benzamidosulfonyl, etc.] were prepared Thus, (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(3-sulfophenylcarbamoyl)pyrrolidin-4-ylthioacetate diisopropylethylamine salt (preparation given) was saponified with 1N NaOH and the resulting thiol was stirred with 4-nitrobenzyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (preparation given) in DMF containing diisopropylethylamine and Bu3P to give a coupling product which was hydrogenated in EtOAc/H2O/EtOH containing KHCO3 to give (1S,5S,6S,8R,2'S,4'S)-2-[2-(3-sulfophenylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid dipotassium salt. This showed MIC's of 0.125 and 0.015 μg/mL against Staphylococcus aureus Oxford and Escherichia coli DC0, resp.

ACCESSION NUMBER: 1994:269929 HCAPLUS
DOCUMENT NUMBER: 120:269929
TITLE: Preparation of (carbamoylpyrrolidinylthio)carbapenems as antibiotics
INVENTOR(S): Jung, Frederic Henri; Bertrandie, Alain Michel; Galt, Ronald Hilson Begg
PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca-Pharma
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 562855	A1	19930929	EP 1993-302296	19930325
EP 562855	B1	19990512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2091309	AA	19930927	CA 1993-2091309	19930309
AT 179978	E	19990515	AT 1993-302296	19930325
ES 2133358	T3	19990916	ES 1993-302296	19930325
JP 06025244	A2	19940201	JP 1993-68076	19930326
US 5571805	A	19961105	US 1994-302394	19940908
PRIORITY APPLN. INFO.:			EP 1992-400837 A	19920326
			EP 1992-400839 A	19920326

L8 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

	EP 1992-402700	A 19921002
	US 1993-37171	B1 19930326

OTHER SOURCE(S): MARPAT 120:269929
IT 154308-86-8P 154308-87-9P 154308-88-0P
154308-89-1P 154308-90-4P 154308-91-5P
154308-93-7P 154309-01-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for antibacterial)
RN 154308-86-8 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-[(2-propenyloxy)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154308-87-9 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-carboxy-2-thienyl]amino]carbonyl]-, 1-[(4-nitrophenyl)methyl] ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154308-88-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-[[(methylsulfonyl)amino]carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 154308-89-1 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-mercapto-2-[[[5-[[(methylsulfonyl)amino]carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154308-90-4 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-3-[[5-[[[5-[[(methylsulfonyl)amino]carbonyl]-2-thienyl]amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 154308-91-5 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[[[5-[(cyanoamino)carbonyl]-2-thienyl]amino]carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154308-93-7 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[[5-[(cyanoamino)carbonyl]-2-thienyl]amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-, compd. with N-ethyl-N-(1-methylethyl)-2-propanamine (1:1) (9CI) (CA INDEX NAME)

L8 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 1

CRN 154308-92-6
CMF C36 H33 N7 O12 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 7087-68-5
CMF C8 H19 N

L8 ANSWER 27 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 154309-01-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[5-[(cyanoamino)carbonyl]-2-thienyl]amino]carbonyl]-4-mercapto-, (4-nitrophenyl)methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Mar 1994
GI



I

AB Title compds. I (n = 0-6; A = bond, acylyl, aromatic heterocyclyl; X1 = bond, NHCO, CONH; X2, X3 = CONH, NHCO; R1, R2 = oxiranomethyl, 1-aziridinomethyl, (substituted) C2-4 alkyl, C2-4 alkoxyhalo, R4O2SO wherein R4 = C1-4 alkyl, Ph; R1 = H, R2 = R3(CH2)mCO wherein R3 = halo, oxiranyl, methyloxiranyl, aziridinyl, cyclopropyl, (substituted) C2-6 alkenyl, etc.) useful as anticancer and antivirus agents (no data), are prepared 4-(H2N)C6H4N(HOCH2CH2)2 in MeOH was added to a C6H6 solution of 1-methyl-2-carbomethoxy-4-pyrrolecarbonylic acid to give Me 1-methyl-4-[4-[N,N-bis(2-hydroxyethyl)amino]benzeneaminocarbonyl]pyrrole-2-carboxylate which was saponified to the free acid which was converted to bis(2-chloroethyl derivative which in DMF was added to 1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamidopropionamidino-HCl, N-hydroxybenzotriazole, 1,8-bis(dimethylamino)naphthalene and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide to give the title I (n = 0, A = p-phenylene, X1 = HNCO, X2 = X3 = CONH, R1 = R2 = ClCH2CH2).HCl.

ACCESSION NUMBER: 1994:107751 HCAPLUS
DOCUMENT NUMBER: 120:107751
TITLE: Preparation of retroreverse pyrrole-amidino oligopeptide anticancer agent analogues
INVENTOR(S): Arcamone, Federico; Lombardi, Paolo; Animati, Fabio
PATENT ASSIGNEE(S): Menarini, A., Industrie Farmaceutiche Riunite S.r.l., Italy; Bristol-Myers Squibb S.p.A.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9313739	A2	19930722	WO 1993-EP2	19930104
WO 9313739	A3	19931125		
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9333478	A1	19930803	AU 1993-33478	19930104
EP 623023	A1	19941109	EP 1993-902141	19930104
R: DE, ES, FR, GB				

PRIORITY APPLN. INFO.: IT 1992-MI21 A 19920110
WO 1993-EP2 A 19930104

OTHER SOURCE(S): MARPAT 120:107751
IT **150691-25-1P 150691-26-2P 150691-27-3P**

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



● HCl

RN 150691-27-3 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[[4-[bis(2-chloroethyl)amino]-2-thienyl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
150691-28-4P 150691-29-5P 150691-30-8P
150691-31-9P 150691-33-1P 150691-34-2P
150691-35-3P 150691-36-4P 150691-40-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as anticancer and antivirus agent)
RN 150691-25-1 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-[5-[[[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]carbonyl]amino]-1-methyl-1H-pyrrol-3-yl]-N4-[4-[bis(2-chloroethyl)amino]phenyl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

RN 150691-26-2 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N4-[4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 150691-28-4 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[[4-[bis(2-chloroethyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 150691-29-5 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[bis(2-chloroethyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 150691-30-8 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N4-[4-[bis(2-chloroethyl)amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 150691-31-9 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[bis(2-chloroethyl)amino]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A

● HCl

RN 150691-34-2 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[(cyclopropylcarbonyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● HCl

RN 150691-35-3 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[(1-aziridinylcarbonyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 150691-33-1 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-1-methyl-N4-[1-methyl-4-[[[1-methyl-4-[[(3-methyloxiranyl)carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

● HCl

RN 150691-36-4 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[(2-chloro-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 150691-40-0 HCAPLUS

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-2,4-dicarboxamide, N2-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N4-[4-[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● HCl

IT 150691-42-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of anticancer and antivirus agents)
RN 150691-42-2 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-amino-N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-,

L8 ANSWER 28 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 29 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Jan 1994
AB High resolution proton NMR techniques have been used to study the interaction between the self-complementary Dickerson dodecamer d(CGCGAATTCGCG)2 and two distamycin analogs containing a retroinverted amide bond. The results indicated that both analogs, although binding the Dickerson dodecamer less strongly than distamycin, span the central AATT segment in the minor groove in a similar fashion.
ACCESSION NUMBER: 1994:2947 HCAPLUS
DOCUMENT NUMBER: 120:2947
TITLE: Proton NMR studies of the interactions of two distamycin analogs with the dodecamer d(CGCCAATTCGCG)2
AUTHOR(S): Rosaria Conte, Maria; Fattorusso, Ernesto; Gomez-Paloma, Luigi; Mayol, Luciano
CORPORATE SOURCE: Dip. Chim. Sostanze Nat., Univ. Napoli Federico, Naples, I-80131, Italy
SOURCE: Bioorganic & Medicinal Chemistry Letters (1992), 2(10), 1299-304
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 143158-57-0
RL: PRP (Properties)
(double-stranded DNA dodecamer binding of, NMR study of)
RN 143158-57-0 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-(4-[[[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)



L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Oct 1993
GI



AB The title compds. I [W = O, S, NH; m, n = 1, 2, 3, 4; B, B1 = (CH2)pNR1R2, (CH2)qC(:NR3)NR4R5, B, B1 = (un)saturated (un)substituted (condensed) carbocyclic ring; (un)saturated (un)substituted heteromono- or -di-cycle; p = 2, 3, 4; R1, R2 = H, C1-6 alkyl; q = 1, 2, 3, 4; R3 = H, R4, R5 = H, C1-6 alkyl; R3R4 = CH:CH, CH2CH2, CH2CH2CH2; R5 = H, C1-6 alkyl;] and their pharmaceutically acceptable salts, useful as angiogenesis inhibitors (no data) and particularly in cancer therapy either alone or together with an antitumor agent, are prepd from aminomethylpyrrolecarboxamide derivs., e.g., II [W1 = O, S; X = leaving group) or their salts. Thus, 8,8'-[carbonylbis[imino-N-methyl-5,3-pyrrolecarbonylimino(N-methyl-5,3-pyrrole)carbonylimino]]bis[1-(N,N-dimethylamino)naphthalene was prepared from 1,8-diaminonaphthalene and Me 5-nitro-3-pyrrolecarboxylate in several of steps.
ACCESSION NUMBER: 1993:539084 HCAPLUS
DOCUMENT NUMBER: 119:139084
TITLE: Derivatives of 5-amino-1-methyl-3-pyrrolecarboxamides as angiogenesis inhibitors
INVENTOR(S): Mongelli, Nicola; Biasoli, Giovanni; Paio, Alfredo; Mariani, Mariangela
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.r.l., Italy
SOURCE: Brit. UK Pat. Appl., 43 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2260134	A1	19930407	GB 1991-21205	19911004
PRIORITY APPLN. INFO.:			GB 1991-21205	19911004

OTHER SOURCE(S): MARPAT 119:139084
IT 149621-64-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)
RN 149621-64-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[[[8-(dimethylamino)-1-naphthalenyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-5-nitro-

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



IT **149594-72-9P 149594-73-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reaction of in synthesis of angiogenesis inhibitor)
RN 149594-72-9 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8-[[[5-[[[5-amino-1-methyl-1H-pyrrol-3-yl]carbonyl]amino]-1-methyl-1H-pyrrol-3-yl]carbonyl]amino]-, trisodium salt, monohydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

● HCl

●3 Na

RN 149594-73-0 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8-[[[1-methyl-5-[[[1-methyl-5-nitro-1H-pyrrol-3-yl)carbonyl]amino]-1H-pyrrol-3-yl]carbonyl]amino]-, trisodium salt (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

●3 Na

IT **149594-76-3P 149621-63-6P 149621-70-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as angiogenesis inhibitor)
RN 149594-76-3 HCAPLUS
CN 1,3-Naphthalenedisulfonic acid, 7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis-, tetrapotassium salt (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

●4 K

RN 149621-63-6 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5,5'-(carbonyldiimino)bis[N-[4-[[[8-(dimethylamino)-1-naphthalenyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 149621-70-5 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 149594-70-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, in synthesis of angiogenesis inhibitor)
RN 149594-70-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5-amino-N-[4-[[[8-(dimethylamino)-1-naphthalenyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 149594-71-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, protonation, and formulation of, as angiogenesis inhibitor)
RN 149594-71-8 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis-, hexasodium salt (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

IT 149594-77-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in synthesis of angiogenesis inhibitor)
RN 149594-77-4 HCAPLUS
CN 1,3-Naphthalenedisulfonic acid, 7-[[[5-[[(5-amino-1-methyl-1H-pyrrol-3-yl)carbonyl]amino]-1-methyl-1H-pyrrol-3-yl]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 149621-72-7 149621-73-8 149621-74-9
149621-75-0 149621-76-1 149621-77-2
149621-78-3 149621-79-4 149621-80-7
149621-81-8 149621-82-9 149621-83-0
149621-84-1 149621-85-2 149621-86-3
149621-87-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(use of, as angiogenesis inhibitor)
RN 149621-72-7 HCAPLUS
CN 1H-Pyrrole-3-carboxamide, 5,5'-(carbonyldiimino)bis[N-[4-[[[4-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





PAGE 2-B

RN 149621-73-8 HCAPLUS
CN Carbonimidic dihydrazide, 2,2'-bis[4-[[[4-[[[4-[[(3-amino-3-

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 149621-74-9 HCAPLUS
CN 1-Naphthalenesulfonic acid, 4,4'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 149621-75-0 HCAPLUS
CN 1-Naphthalenesulfonic acid, 8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149621-76-1 HCAPLUS
CN 1,3-Naphthalenedisulfonic acid, 8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)



RN 149621-77-2 HCAPLUS
CN 1,7-Naphthalenedisulfonic acid, 4,4'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 149621-78-3 HCAPLUS
CN 1,5-Naphthalenedisulfonic acid, 4,4'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 149621-79-4 HCAPLUS
CN 1,3,6-Naphthalenetrisulfonic acid, 8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 149621-80-7 HCAPLUS
CN 1,5-Naphthalenedisulfonic acid, 7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149621-81-8 HCAPLUS
CN 1,3-Naphthalenedisulfonic acid, 6,6'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)



RN 149621-82-9 HCAPLUS
CN 1,7-Naphthalenedisulfonic acid, 3,3'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149621-83-0 HCAPLUS
CN 2,7-Naphthalenedisulfonic acid, 3,3'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 149621-84-1 HCAPLUS
CN 1,3,5-Naphthalenetrisulfonic acid, 7,7'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)



RN 149621-85-2 HCAPLUS
CN 1,3-Naphthalenedisulfonic acid, 7,7'-[carbonothioylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis- (9CI) (CA INDEX NAME)

L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 149621-87-4 HCAPLUS
CN D-Glucose, 2,2'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis(2-deoxy-, 6,6'-(dihydrogen phosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149621-86-3 HCAPLUS
CN D-Glucose, 2,2'-[carbonylbis[imino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino(1-methyl-1H-pyrrole-2,4-diyl)carbonylimino]]bis[2-deoxy-, 6,6'-bis(hydrogen sulfate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L8 ANSWER 30 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



L8 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 18 Sep 1993
AB Comparison of the DNA cleavage activity of man-designed bleomycins demonstrates that bleomycins are small enzymes comprised of the catalytic site and a binding site. The linker moiety is shown to be significant for DNA binding, and inversion of its stereochem. results in a dramatic decrease in the DNA-cleaving efficiency. It can be said that bleomycin possesses a switching device in the β-aminoalaninamide moiety to regulate the in vivo activity. One of the man-designed BLMs shows excellent cytotoxicity against L1210.
ACCESSION NUMBER: 1993:508375 HCAPLUS
DOCUMENT NUMBER: 119:108375
TITLE: Man-designed bleomycins based on the anticancer mechanism of natural bleomycins: Significance of the binding sites as enzyme models, of the stereochemistry of the linker moiety, and of a switching device in the β-aminoalaninamide moiety
AUTHOR(S): Ohno, Masaji
CORPORATE SOURCE: Fac. Pharm. Sci., Univ. Tokyo, Tokyo, Japan
SOURCE: Proceedings of the Robert A. Welch Foundation Conference on Chemical Research (1991), 35(Chem. Front. Med.), 119-34
CODEN: PRAWAC; ISSN: 0557-1588
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **149352-73-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(deprotection of)
RN 149352-73-8 HCAPLUS
CN Carbamic acid, [4-[[5-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **149330-07-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and coupling of, with distamycin)
RN 149330-07-4 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-[[[5-[(4-amino-1-oxobutyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-N-[5-[[[3-(dimethylamino)propyl]amino]carbonyl

L8 ANSWER 31 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
]-1-methyl-1H-pyrrol-2-yl]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

L8 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 07 Aug 1993
AB Nonintercalating DNA minor-groove binders may effectively inhibit the supercoiling activity of DNA gyrase (I) by influencing the enzyme recognition and cleavage site on DNA. For I from Streptomyces noursei, a wide range of inhibitory potency for different classes of ligands was observed This could be explained by a number of structural and binding factors of the ligands competing with I on the target site of DNA, the mechanism of which is different from the classical I inhibitors.
ACCESSION NUMBER: 1993:443973 HCAPLUS
DOCUMENT NUMBER: 119:43973
TITLE: Minor-groove binders are inhibitors of the catalytic activity of DNA gyrases
AUTHOR(S): Stoerl, K.; Stoerl, J.; Zimmer, Ch.; Lown, J. W.
CORPORATE SOURCE: Dep. Mol. Biol., Inst. Mol. Biol., Univ. Jena, Jena, Germany
SOURCE: FEBS Letters (1993), 317(1-2), 157-62
CODEN: FEBLAL; ISSN: 0014-5793
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **148504-19-2 148504-20-5 148504-21-6**
RL: BIOL (Biological study)
(DNA gyrase of Streptomyces noursei inhibition by, mechanism of)
RN 148504-19-2 HCAPLUS
CN Heptanediamide, N,N'-bis[5-[[[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 148504-20-5 HCAPLUS
CN Octanediamide, N,N'-bis[5-[[[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L8 ANSWER 32 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 148504-21-6 HCAPLUS
CN Decanediamide, N,N'-bis[5-[[[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L8 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 04 Oct 1992
AB HX1ZX2ZX3ZCONHCH2CH2C(:NH)NH2 (X1, X2, X3 = CONH or NHCO the case wherein X1 = X2 = X3 = CONH being excluded; Z = 1-methyl-2,4-pyrrolylene throughout) were prepared as antiviral and antitumor agents (no data). Thus, HO2C2CO2Me and O2NZCON3 (preparation each given) were heated with Et3N and the product converted in 3 steps to O2NZNHCOZCONHCH2CH2C(:NH)NH2 which was hydrogenated and the product condensed with HCONHZCO2H (preparation given) to give HCONHZCONHZNHCOZCONHCH2CH2C(:NH)NH2.

ACCESSION NUMBER: 1992:530993 HCAPLUS
DOCUMENT NUMBER: 117:130993
TITLE: Preparation of distamycin analogs as antiviral antitumor agents
INVENTOR(S): Animati, Fabio; Arcamone, Federico; Lombardi, Paolo; Rossi, Cristina
PATENT ASSIGNEE(S): Menarini, A., Industrie Farmaceutiche Riunite S.r.l., Italy; Bristol-Myers Squibb S.p.A.
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9209574	A2	19920611	WO 1991-EP2220	19911120
WO 9209574	A3	19920806		
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MC, MG, MN, MW, NO, PL, RO, SD, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9189178	A1	19920625	AU 1991-89178	19911120
PRIORITY APPLN. INFO.:			IT 1990-22154 A	19901122
			WO 1991-EP2220 A	19911120

OTHER SOURCE(S): MARPAT 117:130993
IT **143158-63-8P 143158-64-9P 143158-65-0P 143363-83-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antiviral and antitumor agents)
RN 143158-63-8 HCAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 1-methyl-4-[[(1-methyl-4-nitro-1H-pyrrol-2-yl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 143158-64-9 HCAPLUS

L8 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-2-carboxylic acid, 1-methyl-4-[[(1-methyl-4-nitro-1H-pyrrol-2-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 143158-65-0 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(2-cyanoethyl)-1-methyl-N4-(1-methyl-4-nitro-1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 143363-83-1 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-1-methyl-N4-(1-methyl-4-nitro-1H-pyrrol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **143158-57-0P 143158-59-2P 143158-60-5P 143158-61-6P 143158-66-1P 143158-67-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiviral and antitumor agent)
RN 143158-57-0 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)

L8 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 143158-59-2 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N4-[4-[[[4-(aminocarbonyl)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-N2-(3-amino-3-iminopropyl)-1-methyl- (9CI) (CA INDEX NAME)



RN 143158-60-5 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N4-[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]-1-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 143158-61-6 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N4-[4-(aminocarbonyl)-1-methyl-1H-pyrrol-2-yl]-N2-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 143158-66-1 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-(formylamino)-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 33 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 143158-67-2 HCAPLUS
CN 1H-Pyrrole-2,4-dicarboxamide, N4-[4-[[[4-(aminocarbonyl)-1-methyl-1H-pyrrol-2-yl]amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-N2-(3-amino-3-iminopropyl)-1-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 34 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 23 Aug 1992
AB Various aliphatic N-acyl derivs. and an N-phthalidyl derivative of the model compound N-benzyloxycarbonyl-glycyl-L-prolineamide (Z-Gly-ProNH2) were synthesized to assess their suitability as prodrug forms for the C-terminal prolineamide residue occurring in several peptides (e.g. TRH) with the aim of protecting the peptide against prolyl endopeptidase in the gut prior to absorption. Whereas Z-Gly-ProNH2 was rapidly hydrolyzed in a rabbit gut homogenate, used as a source of prolyl endopeptidase, the N-acyl derivs. were found to afford protection by a factor of 1.5-6. The stability of the N-acyl derivs. in the gut homogenate decreased with increasing chain length within the acyl group. The N-phthalidyl derivative, on the other hand, degraded even faster than the parent compound The derivs. were all converted quant. into the parent peptide in human plasma solns. via hydrolysis catalyzed by non-specific plasma esterases. The results suggest that by appropriate N-acylation it may be feasible to improve the stability of a C-terminal prolineamide moiety toward prolyl endopeptidase. The combination of increased stability in the intestine and higher lipophilicity of the N-acyl prodrugs might render it possible to improve the delivery characteristics of peptides containing a C-terminal prolineamide moiety.
ACCESSION NUMBER: 1992:476326 HCAPLUS
DOCUMENT NUMBER: 117:76326
TITLE: Prodrugs of peptides. 17. Bioreversible derivatization of the C-terminal prolineamide residue in peptides to afford protection against prolyl endopeptidase
AUTHOR(S): Moess, Judi; Bundgaard, Hans
CORPORATE SOURCE: Dep. Pharm. Chem., R. Dan. Sch. Pharm., Copenhagen, Den.
SOURCE: International Journal of Pharmaceutics (1992), 82(1-2), 91-7
CODEN: IJPHDE; ISSN: 0378-5173
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **142755-61-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of, for protection against prolyl endopeptidase)
RN 142755-61-1 HCAPLUS
CN L-Prolinamide, N-[(phenylmethoxy)carbonyl]glycyl-N-(1,3-dihydro-3-oxo-1-isobenzofuranyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 17 Apr 1992
GI



I



II

AB Title compds. [I; A = (un)substituted N-containing heterocyclylenediyl; Q = BN+R8R9R10, heterocyclyl, heterocyclylalkyl; B = alkylene alkylidene; R1 = H, Me; R2 = H, alkyl; NQR2 = heterocyclyl group Q1; R3 = H, neg. charge; R6 = (un)substituted alkyl; R7-R10 = alkenyl, alkynyl, (un)substituted alkyl; m, n = 0-2] were prepared Thus, (2S,4S)-4-(4-methoxybenzylthio)-2-pyrrolidinecarboxylic acid was N-protected and the product amidated with N-methylpiperazine to give, after hydrolysis, (2S,4S)-4-mercapto-2-(4-methyl-1-piperazinylcarbonyl)-1-(4-nitrobenzyloxycarbonyl)pyrrolidine. The latter was stirred 5 h at .apprx.0° with 4-nitrobenzyl (1R,5R,6S)-6-[(1R)-hydroxymethyl]-1-methyl-2-oxo-1-methyl-2-oxo-1-carbapenem-3-carboxylate which had been treated with Ph2P(O)Cl and the product treated with FSO2OMe followed by catalytic hydrogenolysis to give title compound (1R,5S,6S)-II which had MIC of ≤0.01 (no units given) against Staphylococcus aureus 209P and Escherichia coli NIHJ. I are resistant to dehydropeptidase I and β-lactamase.
ACCESSION NUMBER: 1992:151432 HCAPLUS
DOCUMENT NUMBER: 116:151432
TITLE: Preparation of [(piperaziniocarbonyl)pyrrolidinylthio] carbapenems and analogs as antibiotics
INVENTOR(S): Kawamoto, Isao; Miyauchi, Masao; Nakayama, Eiji; Endo, Rokuro; Ohya, Satoshi; Utsui, Yukio
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 117 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 443883	A1	19910828	EP 1991-301497	19910225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 04211083	A2	19920803	JP 1991-27059	19910221
CA 2036941	AA	19910824	CA 1991-2036941	19910222
FI 9100860	A	19910824	FI 1991-860	19910222

L8 ANSWER 35 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

FI 96863	B	19960531		
FI 96863	C	19960910		
NO 9100723	A	19910826	NO 1991-723	19910222
NO 178498	B	19960102		
NO 178498	C	19960410		
AU 9171322	A1	19910829	AU 1991-71322	19910222
AU 646012	B2	19940203		
HU 58100	A2	19920128	HU 1991-620	19910225
ZA 9101344	A	19921125	ZA 1991-1344	19910225
CZ 289263	B6	20011212	CZ 1991-483	19910225
US 5310735	A	19940510	US 1992-938483	19920831
RU 2059639	C1	19960510	RU 1993-4744	19930315
US 5420119	A	19950530	US 1993-143996	19931027

PRIORITY APPLN. INFO.:
JP 1990-42796 A 19900223
JP 1990-212283 A 19900810
US 1991-658975 B1 19910221
US 1992-938483 A3 19920831
US 1993-60817 B1 19930512

OTHER SOURCE(S): MARPAT 116:151432
IT **138508-14-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antibiotics)
RN 138508-14-2 HCAPLUS
CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-3-[[5-[[(1-methyl-2-pyrrolidinyl)amino]carbonyl]-1-[[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-7-oxo-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 05 Oct 1991
AB Bifunctional mols., e.g. tri-, tetra-, penta-, and hexa-N-methylpyrrolecarboxamide-EDTA, bis(EDTA-distamycin), etc., are prepared by reacting a DNA intercalator (p-carboxymethidium, etc.) or DNA groove binder (netropsin, distamycin, etc.) with 1,3-diaminopropane followed by condensation with EDTA. These mols. are used for cleaving single- or double-stranded DNA in the presence of Fe(II) and O with sequence specificity which is either similar to or not available with naturally occurring restriction enzymes. Thus, bis(EDTA-distamycin)phenoxazone was prepared by using 3-benzyloxy-4-methyl-2-nitrobenzoic acid and 4-nitro-tri-N-methylpyrrole-2-carboxylic acid as starting materials, and showed 100% cleavage of plasmid pBR322 DNA at ≥0.1 μM in the presence of Fe(II), O, and dithiothreitol.
ACCESSION NUMBER: 1991:531393 HCAPLUS
DOCUMENT NUMBER: 115:131393
TITLE: Preparation of bifunctional molecules having a DNA intercalator or DNA groove binder linked to EDTA for cleaving double-stranded DNA
INVENTOR(S): Dervan, Peter B.; Hertzberg, Robert P.
PATENT ASSIGNEE(S): California Institute of Technology, USA
SOURCE: U.S., 59 pp. Cont.-in-part of U.S. 4,665,184.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4942227	A	19900717	US 1987-6442	19870123
US 4665184	A	19870512	US 1986-860604	19860507
PRIORITY APPLN. INFO.:			US 1982-338327	B2 19820111
			US 1983-540914	B1 19831012
			US 1986-860604	A2 19860507
			US 1982-338332	A2 19820111

OTHER SOURCE(S): MARPAT 115:131393
IT 134986-15-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reaction of, in preparation of bifunctional mols. having a DNA intercalator or DNA groove binder linked to EDTA for specific DNA cleavage)
RN 134986-15-5 HCAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[[5-[[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxobutyl]amino]-1-methyl-1H-pyrrol-3-yl]carbonyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 36 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L8 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 08 Dec 1990
GI



AB Title compds. I [R2 = H, alkyl, Cl, (un)substituted Ph, (un)substituted PhCH2; R4 = H, 1 or 2 substituents such as alkyl, HO, alkoxy, halo in 4-, 5-, 6-, or 7 position; alk = (un)substituted α,ω-alkylene (CH2)n; n = 2-6; NB = N3, H2N, alkylamino, hydroxyalkylamino, morpholino, thiomorpholino, piperidino, pyrrolidino, azetidino, pyrrolidino, 1-piperazinyl, hexahydro-4H-1,4-diazepinyl, their oxides, etc.] or an acid addition salt thereof, useful as analgesics (no data) are prepared II (R = R3CZ, R3COCH:CH, R3CO; R3 = cyclohexyl, heterocycylphenyl, aminomethylphenyl, (un)substituted styryl, biphenyl, (un)substituted naphthyl, heterocyclyl, etc.; CZ = CO, HONC; R1 = H, BNAlk, BNCH2CH(OH)CH2] were also prepared and found to possess analgesic, antiinflammatory and antirheumatic activities. II [R = 3-(O2N)C6H4CO; R1 = 2-morpholinoethyl; R2 = Me; R4 = H] in EtOAc and AcOH was reduced with H over Pt oxide to give 83% II [R = 3-(H2N)C6H4CO; R4 = morphoninoethyl; R2 = Me; R4 = H] (III). III, on oral administration, showed and ED50 in acetylcholine-induced abdominal constriction and antibradykinin test of 16 and 53 mg, resp., and on the rat paw flexion test 0.12% at 100 mg/kg.
ACCESSION NUMBER: 1990:611828 HCAPLUS
DOCUMENT NUMBER: 113:211828
TITLE: Preparation of 1-(aminoalkyl)indoles useful as analgesic agents or as intermediates and their production processes
INVENTOR(S): Bell, Malcolm R.
PATENT ASSIGNEE(S): Sterling Drug Inc., USA
SOURCE: Can., 114 pp. Division of Can. Appl. No. 488,073.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1258070	A2	19890801	CA 1988-576124	19880830
US 4581354	A	19860408	US 1985-755239	19850715
CA 1246563	A1	19881213	CA 1985-488073	19850802
US 4634776	A	19870106	US 1985-810942	19851219
US 32761	E	19881004	US 1987-29302	19870323
CA 1255305	A2	19890606	CA 1988-576122	19880830
CA 1255316	A2	19890606	CA 1988-576123	19880830
CA 1255312	A2	19890606	CA 1988-576125	19880830
CA 1258069	A2	19890801	CA 1988-576121	19880830
US 4885295	A	19891205	US 1988-255305	19881011
FI 8903253	A	19890704	FI 1989-3253	19890704
FI 8903254	A	19890704	FI 1989-3254	19890704
FI 8903255	A	19890704	FI 1989-3255	19890704
FI 8903256	A	19890704	FI 1989-3256	19890704
FI 8903257	A	19890704	FI 1989-3257	19890704
US 4978664	A	19901218	US 1989-409913	19890920
NO 9003304	A	19860207	NO 1990-3304	19900725

L8 ANSWER 37 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

NO 9003305	A	19860207	NO 1990-3305	19900725
NO 9003306	A	19860207	NO 1990-3306	19900725
US 5013732	A	19910507	US 1990-559787	19900730
PRIORITY APPLN. INFO.:			US 1984-637931	A 19840806
			US 1985-755239	A 19850715
			CA 1985-488073	A3 19850802
			FI 1985-2973	A 19850801
			NO 1985-3066	A1 19850802
			US 1985-810942	A3 19851219
			US 1986-928335	A1 19861107
			US 1988-255305	A3 19881011
			US 1989-409913	A3 19890920

OTHER SOURCE(S): CASREACT 113:211828; MARPAT 113:211828
IT 125019-12-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as analgesic, antiinflammatory, and antirheumatic)
RN 125019-12-7 HCAPLUS
CN 1H-Indole-3-carboxamide, N-methyl-1-[1-methyl-2-(4-morpholinyl)ethyl]-N-1H-pyrrol-2-yl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L8 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 21 Jan 1989
GI



I

AB The title compds. [I; R1, R2 = H, C1-6 alkyl, C3-7 cycloalkyl, (un)substituted heterocyclyl; X = H, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, Br, Cl, F; Y = X, C3-6 cycloalkyl, CF3, NO2, MeCO, EtCO, PrCO, PhCO, thenoyl; adjacent XY = OCH2O] were prepared as inflammation inhibitors and analgesics (no data). To a slurry of 13.3 g oxindole (2-indolinone) in PhMe was added 15.6 g ClSO2NCO and the mixture heated on a steam bath to give 1-[(chlorosulfonyl)carbamoyl]oxindole which was heated in aqueous HOAc to give 11.48 g 1-carbamoyloxindole. The latter (1.0 g) and 1.28 g 2,4-Cl2C6H3NCO were stirred at 1 h 0-5° in DMF containing Et3N, followed by addition of 1N HCL and stirring 20 min. to give 290 mg I (R1 = 2,4-Cl2C6H3, R2 = X = Y = H).

ACCESSION NUMBER: 1989:23728 HCAPLUS
DOCUMENT NUMBER: 110:23728
TITLE: Preparation of oxindole-1,3-dicarboxamides as antiinflammatory agents
INVENTOR(S): Kadin, Saul B.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 30 pp. Cont.-in-part of U.S. Ser. No. 753,200, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4725616	A	19880216	US 1987-8105	19870120
ZA 8605019	A	19880224	ZA 1986-5019	19860707
DD 251971	A5	19871202	DD 1986-292280	19860708
US 4791129	A	19881213	US 1987-118123	19871109
PRIORITY APPLN. INFO.:			US 1985-753200 A2	19850709
			US 1987-8105 A3	19870120

OTHER SOURCE(S): CASREACT 110:23728; MARPAT 110:23728
IT 107315-25-3P 107315-36-6P 107315-56-0P
107315-80-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory)
RN 107315-25-3 HCAPLUS
CN 1H-Indole-1,3-dicarboxamide, 2,3-dihydro-2-oxo-N3-2-thienyl- (9CI) (CA INDEX NAME)

L8 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 107315-36-6 HCAPLUS
CN 1H-Indole-1,3-dicarboxamide, 5-chloro-2,3-dihydro-2-oxo-N3-2-thienyl- (9CI) (CA INDEX NAME)



RN 107315-56-0 HCAPLUS
CN 1H-Indole-1,3-dicarboxamide, 2,3-dihydro-N1-(4-methoxyphenyl)-2-oxo-N3-2-thienyl- (9CI) (CA INDEX NAME)



RN 107315-80-0 HCAPLUS
CN 5H-1,3-Dioxolo[4,5-f]indole-5,7-dicarboxamide, 6,7-dihydro-N5-(4-methoxyphenyl)-6-oxo-N7-2-thienyl- (9CI) (CA INDEX NAME)

L8 ANSWER 38 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L8 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 15 May 1987
GI



I



II



III

AB The title compds. [I; n = 0-4; R = NHR3 [R3 = CON(NO)R4 [R4 = C1-4 (halo)alkyl], CO(CH2)mR5 (R5 = halo, oxiranyl, methyloxiranyl, aziridinyl, cyclopropyl, moiety of alicyclic α,β-unsatd. ketone or lactone; m = 0-4)], NR6R7 [R6, R7 = oxiranylmethyl, aziridinylmethyl, substituted C2-4 alkyl; 1 of R6, R7 = H, the other as above], NO2, NH2, NHCHO; R1 = H, C1-6 alkyl; R2 = substituted C1-6 alkyl] and their pharmaceutically tolerable salts, useful as antiviral and antineoplastic agents, were prepared by 6 methods, e.g. reaction of aminopyrrolecarboxamide II (q = 1-5) with nitropyrrole III (Z = leaving group) to give I (R = NO2). 3-[1-Methyl-4-[1-methyl-4-aminpyrrole-2-carbonamido]pyrrole-2-carboxamido]pyrrole-2-carboxamido]propyldimethylamine-2HCl in aqueous NaHCO3 was acylated with 1-methyl-4-nitropyrrole-2-carbonyl chloride in THF at room temperature to give I [R = NO2, R1 = Me, R2 = (CH2)3NMe2, n = 2] (IV). In in vitro tests, IV had an activity index .apprx.8 with herpes simplex-infected Hep #2 cells (activity index = maximum tolerable dose/min inhibitory concentration) and .apprx.4 with Coxsackie B infected Hep #2 cells; compared to .apprx.4 and <1, resp., for distamycin. A formulation for 10,000 tablets comprised IV 500, lactose 1400, cornstarch 500, talcum powder 50, and Mg stearate 20 g.

ACCESSION NUMBER: 1987:156157 HCAPLUS
DOCUMENT NUMBER: 106:156157
TITLE: Poly-4-aminopyrrole-2-carboxamide derivatives, procedure for their preparation, and antiviral and antineoplastic pharmaceuticals containing them
INVENTOR(S): Arcamone, Federico; Mongelli, Nicola; Penco, Sergio
PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.p.A., Italy
SOURCE: Ger. Offen., 35 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3623880	A1	19870129	DE 1986-3623880	19860715
US 4766142	A	19880823	US 1985-783588	19851003
SE 8603098	A	19870117	SE 1986-3098	19860711
SE 468642	B	19930222		
SE 468642	C	19930617		

L8 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AT 8601888	A	19880415	AT 1986-1888		19860711
AT 387013	B	19881125			
AU 8660202	A1	19870122	AU 1986-60202		19860714
AU 587841	B2	19890831			
NL 8601837	A	19870216	NL 1986-1837		19860714
HU 43088	A2	19870928	HU 1986-2904		19860714
HU 205949	B	19920728			
ES 2000502	A6	19880301	ES 1986-290		19860714
IL 79402	A1	19910610	IL 1986-79402		19860714
BE 905110	A1	19870115	BE 1986-216924		19860715
DK 8603359	A	19870117	DK 1986-3359		19860715
NO 8602860	A	19870119	NO 1986-2860		19860715
NO 168826	B	19911230			
NO 168826	C	19920408			
FR 2585018	A1	19870123	FR 1986-10294		19860715
FR 2585018	B1	19890713			
ZA 8605263	A	19870325	ZA 1986-5263		19860715
JP 62077362	A2	19870409	JP 1986-164879		19860715
SU 1544185	A3	19900215	SU 1986-4027809		19860715
CH 674206	A	19900515	CH 1986-2820		19860715
CA 1285934	A1	19910709	CA 1986-513760		19860715
FI 8602959	A	19870117	FI 1986-2959		19860716
FI 83640	B	19910430			
FI 83640	C	19910812			
GB 2178036	A1	19870204	GB 1986-17292		19860716
GB 2178036	B2	19890816			
CN 86104787	A	19870218	CN 1986-104787		19860716
CN 1018825	B	19921028			
CS 276981	B6	19921118	CS 1986-5412		19860716
SU 1609445	A3	19901123	SU 1987-4203699		19871126
PRIORITY APPLN. INFO.:			GB 1985-17922	A	19850716
			GB 1986-13594	A	19860604

IT 107580-36-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiviral and antineoplastic agent)

RN 107580-36-9 HCAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-4-[[[1-methyl-4-[[(1-methyl-4-nitro-1H-pyrrol-2-yl)amino]carbonyl]-1H-pyrrol-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 39 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L8 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN

ED Entered STN: 01 May 1987

GI



I

AB The title compds. I [X = H, Br, Cl, F, C1-4 alkyl, alkylthio, alkoxy, C3-6 cycloalkyl, NO2, CF3, C2-4 acyl, Bz, thenoyl; Y = H, Br, Cl, C1-4 alkyl, alkoxy, alkylthio; optionally XY = 4,5-, 5,6-, 6,7-OCH2O; A = NHR2, R3, NHCOR3; R1, R2 = H, C1-6 alkyl, C3-7 cycloalkyl, heterocyclyl, (substituted)Ph; R3 = C1-6 alkyl, Ph] and their salts, prepared by the reaction of the appropriate oxindole with R1NCO or R1NH2, are useful as antiinflammatory and analgesic agents (no data). To 1-carbamoyloxindole, and Et3N in DMF, was added 2,4-Cl2C6H3NCO to give after addition of 1N HCl I (X = Y = H; A = NH2; R1 = 2,4-Cl2C6H3).

ACCESSION NUMBER:	1987:138254 HCAPLUS
DOCUMENT NUMBER:	106:138254
TITLE:	Preparation of 1-substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents
INVENTOR(S):	Kadin, Saul Bernard
PATENT ASSIGNEE(S):	Pfizer Inc., USA
SOURCE:	Eur. Pat. Appl., 56 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 208510	A2	19870114	EP 1986-305144		19860702
EP 208510	A3	19880302			
EP 208510	B1	19910911			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
US 4678802	A	19870707	US 1986-825017		19860131
AT 67185	E	19910915	AT 1986-305144		19860702
CA 1286663	A1	19910723	CA 1986-513184		19860707
DK 8603242	A	19870110	DK 1986-3242		19860708
FI 8602882	A	19870110	FI 1986-2882		19860708
NO 8602750	A	19870112	NO 1986-2750		19860708
JP 62026269	A2	19870204	JP 1986-160675		19860708
JP 06010193	B4	19940209			
AU 8659847	A1	19870409	AU 1986-59847		19860708
AU 566065	B2	19871008			
HU 41386	A2	19870428	HU 1986-2844		19860708
HU 198015	B	19890728			
ES 2001855	A6	19880701	ES 1986-191		19860708
IL 79356	A1	19900319	IL 1986-79356		19860708
CN 86105309	A	19870114	CN 1986-105309		19860709
ES 2009227	A6	19890916	ES 1987-3589		19871215
PRIORITY APPLN. INFO.:			US 1985-753200	A	19850709
			US 1986-821296	A	19860122
			US 1986-825017	A	19860131
			EP 1986-305144	A	19860702

OTHER SOURCE(S): CASREACT 106:138254

IT 107315-25-3P 107315-36-6P 107315-56-0P

L8 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

107315-80-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as analgesic and antiinflammatory agent)

RN 107315-25-3 HCAPLUS

CN 1H-Indole-1,3-dicarboxamide, 2,3-dihydro-2-oxo-N3-2-thienyl- (9CI) (CA INDEX NAME)



RN 107315-36-6 HCAPLUS

CN 1H-Indole-1,3-dicarboxamide, 5-chloro-2,3-dihydro-2-oxo-N3-2-thienyl- (9CI) (CA INDEX NAME)



RN 107315-56-0 HCAPLUS

CN 1H-Indole-1,3-dicarboxamide, 2,3-dihydro-N1-(4-methoxyphenyl)-2-oxo-N3-2-thienyl- (9CI) (CA INDEX NAME)



RN 107315-80-0 HCAPLUS

CN 5H-1,3-Dioxolo[4,5-f]indole-5,7-dicarboxamide, 6,7-dihydro-N5-(4-

L8 ANSWER 40 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methoxyphenyl)-6-oxo-N7-2-thienyl- (9CI) (CA INDEX NAME)



L8 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI





AB Distamycin A and congocidine isomers and homologs I (R = NO2, HCONH) and II [R1 = NO2, H2NC(:NH)NHCH2CONH] were prepared and their cytotoxicity tested. Thus, acylation of H2NCH2CH2CN by 1-methyl-5-nitro-2-pyrrolecarbonyl chloride gave the pyrrolycarboxamidopropionitrile III, which was treated with EtOH-HCl at 0° for 1 h and then with NH3(g) to give II (R1 = NO2). I were obtained by successive acylation-reduction reactions of 1-methyl-5-nitro-2-carboxylic acid. II (R1 = NO2) possessed the highest antiviral activity in the series, and was less toxic and had the same antiviral activity as distamycin A.

ACCESSION NUMBER: 1981:192034 HCAPLUS
DOCUMENT NUMBER: 94:192034
TITLE: Structure-activity relationships of pyrrole amidine antiviral antibiotics. III: Preparation of distamycin and congocidine derivatives based on 2,5-disubstituted pyrroles
AUTHOR(S): Bialer, Meir; Yagen, Boris; Mechoulam, Raphael; Becker, Yechiel
CORPORATE SOURCE: Pharm. Sch., Hebrew Univ., Jerusalem, Israel
SOURCE: Journal of Pharmaceutical Sciences (1980), 69(11), 1334-8
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 77604-46-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and aminolysis of, carboxamidemide derivative from)
RN 77604-46-7 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(2-cyanoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-5-[[(1-methyl-5-nitro-1H-pyrrol-2-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 77604-47-8P 77604-48-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiviral activity of)
RN 77604-47-8 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-5-[[(1-methyl-5-nitro-1H-pyrrol-2-yl)carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 77604-48-9 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-5-[[[5-(formylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

—NH2

IT 77604-45-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reduction-acylation reactions of)
RN 77604-45-6 HCAPLUS

L8 ANSWER 41 OF 41 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Pyrrole-2-carboxamide, N-[5-[[(2-cyanoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-5-nitro- (9CI) (CA INDEX NAME)



IT 77604-49-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 77604-49-0 HCAPLUS
CN 1H-Pyrrole-2-carboxamide, 5-[[[5-[[[(aminoiminomethyl)amino]acetyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl

PAGE 1-B



Ngrazier 10680346expA2A3A4A6A9

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	204.99	372.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-29.93	-29.93

STN INTERNATIONAL LOGOFF AT 13:53:33 ON 30 AUG 2005





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

Ngrazier 10680346exp3



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:24:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2836 TO ITERATE

 70.5% PROCESSED     2000 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        53526 TO    59914
PROJECTED ANSWERS:           10740 TO    13706

L2            50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:24:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  54653 TO ITERATE

100.0% PROCESSED    54653 ITERATIONS                          11606 ANSWERS
SEARCH TIME: 00.00.04

L3         11606 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               161.76     161.97

FILE 'HCAPLUS' ENTERED AT 17:24:59 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Aug 2005 VOL 143 ISS 10
FILE LAST UPDATED: 29 Aug 2005 (20050829/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1844 L3

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.45	164.42

FILE 'REGISTRY' ENTERED AT 17:25:13 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3
DICTIONARY FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\exp3update.str

Ngrazier 10680346exp3





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 17:26:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2836 TO ITERATE

 70.5% PROCESSED     2000 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        53526 TO    59914
PROJECTED ANSWERS:           10553 TO    13495

L6            50 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 17:26:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  54653 TO ITERATE

100.0% PROCESSED    54653 ITERATIONS                      11202 ANSWERS
SEARCH TIME: 00.00.07

L7         11202 SEA SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\ppp.str
```





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l8
SAMPLE SEARCH INITIATED 17:28:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1636 TO ITERATE

100.0% PROCESSED     1636 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        30294 TO    35146
PROJECTED ANSWERS:               0 TO        0

L9             0 SEA SSS SAM L8

=> s l8 full
FULL SEARCH INITIATED 17:28:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  33735 TO ITERATE

100.0% PROCESSED    33735 ITERATIONS                                  6 ANSWERS
SEARCH TIME: 00.00.01

L10            6 SEA SSS FUL L8

=>
Uploading C:\Program Files\Stnexp\Queries\oooo.str
```





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L11 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l11
SAMPLE SEARCH INITIATED 17:29:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2664 TO ITERATE

```
 75.1% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         50185 TO    56375
PROJECTED ANSWERS:            10244 TO    13144

L12          50 SEA SSS SAM L11

=> fil hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   325.67     490.09

FILE 'HCAPLUS' ENTERED AT 17:30:42 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Aug 2005  VOL 143 ISS 10
FILE LAST UPDATED: 29 Aug 2005  (20050829/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l10
L13          1 L10

=> d ed abs ibib hitstr l13
```

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



I



II

AB Seven compds. with antiulcer activity, produced by Bacillus pumilus strain AI-77 during aerobic culture, have the structures I and II. These compds. also have antiinflammatory, anticholesteremic, antiarrhythmic, and vasodilatory activities and are intermediates for preparation of further compds. with these activities. For example, II-HCl (X = NH; R = R3 = R6 = H; R5 = NH2; R7 = OH) [77715-24-3] was produced by aerobic cultivation of B. pumilus AI-77 in 100 L defatted soybean meal-glucose-salts medium for 20 h at 30°, and was purified from the culture filtrate by chromatog. on Amberlite IRC-50 and XAD-2; the yield was 4.3 g. This compound at 50 mg/kg i.p. provided 100% protection against stress-induced ulcers in rats. The other 6 compds. were produced by B. pumilus in defatted soybean meal-corn steep liquor-sucrose-salts medium and separated by chromatog.

ACCESSION NUMBER: 1981:478461 HCAPLUS
DOCUMENT NUMBER: 95:78461
TITLE: AI-77 compounds and their pharmaceutically acceptable salts
PATENT ASSIGNEE(S): Asahi Chemical Industry Co., Ltd., Japan
SOURCE: Neth. Appl., 221 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 8003985	A	19810113	NL 1980-3985	19800710
NL 187069	B	19901217		
NL 187069	C	19910516		
JP 56012352	A2	19810206	JP 1979-86892	19790711
JP 63034863	B4	19880712		
JP 56158778	A2	19811207	JP 1980-61685	19800512
JP 02046585	B4	19901016		

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GB 2058047	A	19810408	GB 1980-22059	19800704
GB 2058047	B2	19830921		
FR 2476085	A1	19810821	FR 1980-15179	19800708
FR 2476085	B1	19850920		
DE 3026214	A1	19810409	DE 1980-3026214	19800710
DE 3026214	C2	19890803		
CH 654005	A	19860131	CH 1980-5281	19800710
US 4393225	A	19830712	US 1980-167581	19800711
JP 63045274	A2	19880226	JP 1987-109723	19870507
JP 03071428	B4	19911113		

PRIORITY APPLN. INFO.: JP 1979-86892 A 19790711
JP 1980-61685 A 19800512

OTHER SOURCE(S): CASREACT 95:78461

IT 77676-02-9 77676-13-2 77676-14-3
77677-19-1 77677-24-8 77700-94-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(ulcer-inhibiting activity of)

RN 77676-02-9 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-indol-3-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



RN 77676-13-2 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-pyrrol-2-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 77676-14-3 HCAPLUS
CN Hexonic acid, 2,3,6-trideoxy-6-[[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



RN 77677-19-1 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-pyrrol-2-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(8-ethoxy-3,4-dihydro-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



RN 77677-24-8 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-indol-3-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(8-ethoxy-3,4-dihydro-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 77700-94-8 HCAPLUS
CN Hexonic acid, 2,3,6-trideoxy-6-[[1-(8-ethoxy-3,4-dihydro-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



Ngrazier 10680346exp3

=> fil reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 9.84 | 499.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | -0.73 | -0.73

FILE 'REGISTRY' ENTERED AT 17:31:41 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3
DICTIONARY FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\nnn.str



chain nodes :
6 7 8 10 11
ring nodes :

Ngrazier 10680346exp3

1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L14 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\nnn.str





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :

Ngrazier 10680346exp3

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L15 STRUCTURE UPLOADED

=> d l15
L15 HAS NO ANSWERS
L15 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l15
SAMPLE SEARCH INITIATED 17:33:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2836 TO ITERATE

70.5% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 53526 TO 59914
PROJECTED ANSWERS: 10420 TO 13344

L16 50 SEA SSS SAM L15

=> s l15 full
FULL SEARCH INITIATED 17:33:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 54653 TO ITERATE

100.0% PROCESSED 54653 ITERATIONS 11063 ANSWERS
SEARCH TIME: 00.00.04

L17 11063 SEA SSS FUL L15

=>
Uploading C:\Program Files\Stnexp\Queries\yyyy.str





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20
isolated ring systems :
containing 1 : 14 :

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L18 STRUCTURE UPLOADED

=> d l18
L18 HAS NO ANSWERS
L18 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l18
SAMPLE SEARCH INITIATED 17:35:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1019 TO ITERATE

100.0% PROCESSED     1019 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        18465 TO    22295
PROJECTED ANSWERS:           10098 TO    12980

L19          50 SEA SSS SAM L18

=> log y
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               163.48     663.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00      -0.73

STN INTERNATIONAL LOGOFF AT 17:35:22 ON 30 AUG 2005
```





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:24:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2836 TO ITERATE

 70.5% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        53526 TO    59914
PROJECTED ANSWERS:           10740 TO    13706

L2            50 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:24:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  54653 TO ITERATE

100.0% PROCESSED    54653 ITERATIONS                           11606 ANSWERS
SEARCH TIME: 00.00.04

L3         11606 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   161.76     161.97

FILE 'HCAPLUS' ENTERED AT 17:24:59 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Aug 2005 VOL 143 ISS 10
FILE LAST UPDATED: 29 Aug 2005 (20050829/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1844 L3

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.45	164.42

FILE 'REGISTRY' ENTERED AT 17:25:13 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3
DICTIONARY FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\exp3update.str





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l5
SAMPLE SEARCH INITIATED 17:26:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2836 TO ITERATE

 70.5% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         53526 TO    59914
PROJECTED ANSWERS:            10553 TO    13495

L6            50 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 17:26:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  54653 TO ITERATE

100.0% PROCESSED    54653 ITERATIONS                           11202 ANSWERS
SEARCH TIME: 00.00.07

L7         11202 SEA SSS FUL L5

=>
Uploading C:\Program Files\Stnexp\Queries\ppp.str
```





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L8 STRUCTURE UPLOADED

=> d l8
L8 HAS NO ANSWERS
L8 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l8
SAMPLE SEARCH INITIATED 17:28:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1636 TO ITERATE

100.0% PROCESSED     1636 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        30294 TO    35146
PROJECTED ANSWERS:               0 TO        0

L9             0 SEA SSS SAM L8

=> s l8 full
FULL SEARCH INITIATED 17:28:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  33735 TO ITERATE

100.0% PROCESSED    33735 ITERATIONS                                  6 ANSWERS
SEARCH TIME: 00.00.01

L10            6 SEA SSS FUL L8

=>
Uploading C:\Program Files\Stnexp\Queries\oooo.str
```





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L11 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l11
SAMPLE SEARCH INITIATED 17:29:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2664 TO ITERATE

```
 75.1% PROCESSED     2000 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        50185 TO    56375
PROJECTED ANSWERS:           10244 TO    13144

L12          50 SEA SSS SAM L11

=> fil hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   325.67     490.09

FILE 'HCAPLUS' ENTERED AT 17:30:42 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Aug 2005  VOL 143 ISS 10
FILE LAST UPDATED: 29 Aug 2005  (20050829/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l10
L13          1 L10

=> d ed abs ibib hitstr l13
```

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 12 May 1984
GI



I



II

AB Seven compds. with antiulcer activity, produced by Bacillus pumilus strain AI-77 during aerobic culture, have the structures I and II. These compds. also have antiinflammatory, anticholesteremic, antiarrhythmic, and vasodilatory activities and are intermediates for preparation of further compds. with these activities. For example, II-HCl (X = NH; R = R3 = R6 = H; R5 = NH2; R7 = OH) [77715-24-3] was produced by aerobic cultivation of B. pumilus AI-77 in 100 L defatted soybean meal-glucose-salts medium for 20 h at 30°, and was purified from the culture filtrate by chromatog. on Amberlite IRC-50 and XAD-2; the yield was 4.3 g. This compound at 50 mg/kg i.p. provided 100% protection against stress-induced ulcers in rats. The other 6 compds. were produced by B. pumilus in defatted soybean meal-corn steep liquor-sucrose-salts medium and separated by chromatog.

ACCESSION NUMBER: 1981:478461 HCAPLUS
DOCUMENT NUMBER: 95:78461
TITLE: AI-77 compounds and their pharmaceutically acceptable salts
PATENT ASSIGNEE(S): Asahi Chemical Industry Co., Ltd., Japan
SOURCE: Neth. Appl., 221 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 8003985	A	19810113	NL 1980-3985	19800710
NL 187069	B	19901217		
NL 187069	C	19910516		
JP 56012352	A2	19810206	JP 1979-86892	19790711
JP 63034863	B4	19880712		
JP 56158778	A2	19811207	JP 1980-61685	19800512
JP 02046585	B4	19901016		

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GB 2058047	A	19810408	GB 1980-22059	19800704
GB 2058047	B2	19830921		
FR 2476085	A1	19810821	FR 1980-15179	19800708
FR 2476085	B1	19850920		
DE 3026214	A1	19810409	DE 1980-3026214	19800710
DE 3026214	C2	19890803		
CH 654005	A	19860131	CH 1980-5281	19800710
US 4393225	A	19830712	US 1980-167581	19800711
JP 63045274	A2	19880226	JP 1987-109723	19870507
JP 03071428	B4	19911113		

PRIORITY APPLN. INFO.: JP 1979-86892 A 19790711
JP 1980-61685 A 19800512

OTHER SOURCE(S): CASREACT 95:78461

IT 77676-02-9 77676-13-2 77676-14-3
77677-19-1 77677-24-8 77700-94-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(ulcer-inhibiting activity of)

RN 77676-02-9 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-indol-3-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



RN 77676-13-2 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-pyrrol-2-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 77676-14-3 HCAPLUS
CN Hexonic acid, 2,3,6-trideoxy-6-[[1-(3,4-dihydro-8-hydroxy-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



RN 77677-19-1 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-pyrrol-2-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(8-ethoxy-3,4-dihydro-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



RN 77677-24-8 HCAPLUS
CN Hexonic acid, 3-[[(1-acetyl-1H-indol-3-yl)carbonyl]amino]-2,3,6-trideoxy-6-[[1-(8-ethoxy-3,4-dihydro-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 77700-94-8 HCAPLUS
CN Hexonic acid, 2,3,6-trideoxy-6-[[1-(8-ethoxy-3,4-dihydro-1-oxo-1H-2-benzopyran-3-yl)-3-methylbutyl]amino]-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-6-oxo-, γ-lactone (9CI) (CA INDEX NAME)



Ngrazier 10680346exp3

=> fil reg
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 9.84 | 499.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | -0.73 | -0.73

FILE 'REGISTRY' ENTERED AT 17:31:41 ON 30 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3
DICTIONARY FILE UPDATES: 29 AUG 2005 HIGHEST RN 862072-85-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\nnn.str



chain nodes :
6 7 8 10 11
ring nodes :

Ngrazier 10680346exp3

1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L14 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\nnn.str





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :

Ngrazier 10680346exp3

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L15 STRUCTURE UPLOADED

=> d l15
L15 HAS NO ANSWERS
L15 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l15
SAMPLE SEARCH INITIATED 17:33:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2836 TO ITERATE

70.5% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 53526 TO 59914
PROJECTED ANSWERS: 10420 TO 13344

L16 50 SEA SSS SAM L15

=> s l15 full
FULL SEARCH INITIATED 17:33:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 54653 TO ITERATE

100.0% PROCESSED 54653 ITERATIONS 11063 ANSWERS
SEARCH TIME: 00.00.04

L17 11063 SEA SSS FUL L15

=>
Uploading C:\Program Files\Stnexp\Queries\yyyy.str





chain nodes :
6 7 8 10 11
ring nodes :
1 2 3 4 5 14 17 18 19 20
chain bonds :
1-10 6-7 6-8 7-11 7-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 14-17 14-20 17-18 18-19 19-20
exact/norm bonds :
1-2 1-5 1-10 2-3 3-4 4-5 6-7 6-8 7-11 7-14 14-17 14-20 17-18 18-19 19-20
isolated ring systems :
containing 1 : 14 :

G1:H,CH3

G2:O,S

G3:O,N

G4:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 14:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L18 STRUCTURE UPLOADED

=> d l18
L18 HAS NO ANSWERS
L18 STR



G1 H,Me

G2 O,S

G3 O,N

G4 O,S,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l18
SAMPLE SEARCH INITIATED 17:35:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1019 TO ITERATE

100.0% PROCESSED     1019 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        18465 TO    22295
PROJECTED ANSWERS:           10098 TO    12980

L19          50 SEA SSS SAM L18

=> log y
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                163.48     663.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)        SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                  0.00      -0.73

STN INTERNATIONAL LOGOFF AT 17:35:22 ON 30 AUG 2005
```